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Zusammenfassung 
Strukturanalyse von Yersinia-Pyruvat-Kinasen offenbart die 
allosterische Regulierung 
Lebensmittelinfektionen werden in letzter Zeit immer häufiger. Yersinia enterocolitica ist 
eine der pathogenen Bakterien, die die durch Lebensmittel übertragene Krankheit Yersiniose 
verursachen. Die Untersuchung des Stoffwechselsystems von Yersinia enterocolitica wäre 
eine gute Strategie zur Kontrolle der Infektion. Die Pyruvat-Kinase, eines der glykolytischen 
Enzyme, ist hoch reguliert und spielt eine wichtige Rolle bei der Steuerung des 
Stoffwechselflusses. Yersinia hat zwei Arten von Pyruvat-Kinasen, YePykF und YePykA, die 
jeweils allosterisch durch Fructose 1, 6-Bisphosphat (F16BP) bzw. AMP reguliert werden. 
Ungetaggte Yersinia Pyruvat-Kinasen (PK) YePykF und YePykA wurden aus dem E. coli-
Expressionssystem exprimiert und aufgereinigt. Beide PKs wurden allein kristallisiert und 
auch mit ihren allosterischen Effektoren co-kristallisiert. Die Röntgenkristallstrukturen von 
Yersinia-PKs zeigten einen ähnlichen Aufbau wie andere bereits bekannte Pyruvat-Kinasen. 
Der Vergleich zwischen den Strukturen von YePykF- und des YePykF+FBP-Komplexes 
offenbarte Konformationsänderungen sowohl am allosterischen wie am aktiven Zentrum. Bei 
F16BP-Bindung ändert eine Loop-Region des allosterischen Zentrums ihre Konformation 
und die B-Domäne dreht im Durchschnitt um 14,6° in Richtung A-Domäne, was zu einer 
partiellen Schließung des aktiven Zentrums führt. Die YePykA-Struktur wurde nur im 
Komplex mit AMP aufgeklärt. Aufgrund der geringen Qualität des Datensatzes ist die AMP-
Bindungsstelle noch nicht klar. 
Strukturanalyse von Hepatitis C-Virus (HCV) und 
Wirtsrezeptor-Wechselwirkungen 
Das Hepatitis C-Virus (HCV) ist der Haupterreger von akuten und chronischen 
Lebererkrankungen, Leberzirrhose, hepatozellulärem Karzinom und Leberversagen. Rund 
160 Millionen Menschen sind weltweit infiziert, mit geschätzten 130 Millionen chronisch 
Infizierten. Es ist kein Impfstoff verfügbar und die aktuellen Therapien sind nur gegen einige 
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Genotypen wirksam, aber nicht gegen alle. Das Eindringen von HCV in die Wirtszelle 
erfordert das Zusammenwirken zahlreicher Faktoren in zeitlich und räumlich geordneter 
Weise. Die Interaktion des HCV-Hüllproteins E2 und einem Scavenger-Rezeptor Klasse B 
Typ I (SRB1) wird als notwendig für den Prozess des Viruseintritts erachtet. Die 
Strukturuntersuchung von E2 und SRB1 würde wertvolle Informationen zur Blockierung des 
Viruseintritts und damit zur Kontrolle der HCV-Infektion liefern. Die extrazellulären 
Domänen von E2 und SRB1 wurden kloniert und aus verschiedenen eukaryontischen 
Expressionssystemen exprimiert. Die transient in HEK293-Zellen exprimierten Proteine 
zeigten eine hohe Aggregation aufgrund von Fehlfaltung. Später wurde HCV sE2 homogen 
aus einer stabilen CHO- lec 3.8.2.1 Zelllinie exprimiert. Das aufgereinigte SE2 wurde zur 
Kristallisation eingesetzt, es konnte jedoch kein Kristall gewonnen werden. Etwa zur 
gleichen Zeit wie diese Experimente wurden zwei E2-Kernstrukturen ohne die 
hypervariablen Regionen veröffentlicht. Die SRB1-Ektodomäne wurde homogen in 
Insektenzellen exprimiert, und das Protein konnte zu einem hohen Reinheitsgrad aufgereinigt 
werden. Aus unbekanntem Grund konnten die Ergebnisse in späteren Experimenten nicht 
repliziert werden. 
Aufklärung der Autoaktivierungsprozess von Legumain 
Die Cystein-Protease Legumain ist das Nebenprodukt der HCV-sE2-Aufreinigung. CHO- lec 
3.8.2.1 gibt Prolegumain konstitutiv ins Zellkulturmedium ab. Legumain gilt als eine 
Asparaginyl-Endopeptidase, weil es bei pH 5,8 spezifisch nach Asparagin spaltet. Man geht 
davon aus, dass Säugerlegumain in der Immunität, Signaltransduktion, Knochenresorption 
und Tumorwachstum/Metastasierung eine Rolle spielt. Zwei Prolegumain-Strukturen und 
eine aktive Legumain-Struktur wurden in dieser Untersuchung aufgeklärt. Die Tertiärstruktur 
von Prolegumain hat drei Domänen: die C-terminale Legumain-Stabilisierungs- und  
Aktivtätsmodulations-Domäne (legumain stabilization and activity modulation, LSAM), das 
pH-aktivierte Legumain (AEP) und ein Aktivierungspeptid (AP). Bei der pH-Verschiebung 
von neutral zu sauer kann Prolegumain an zwei Schnittstellen gespalten werden, was zu einer 
Freisetzung des AP-Peptids und der C-terminalen LSAM-Domäne führt und so aktives 
Legumain erzeugt. Die hochaufgelöste Struktur von aktivem Legumain zeigt einen 
Succinimidrest im aktiven Zentrum. Das Succinimid wird aus einem Aspartatrest zyklisiert 
und hängt nicht mit Proteinabbau zusammen. Obwohl Kristallisationsplatten mit aktivem 
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Legumain befüllt wurden, zeigen zwei Kristallformen die Prolegumain-Architektur, in der 
die gespaltenen Domänen zusammengehalten, aber nicht ligiert werden. In der Studie von 
Zhao et al. wurde über die Religation von Peptidbindungen in vitro berichtet. Die strukturelle 
Untersuchung von Legumain würde wertvolle Informationen für das Wirkstoffdesign und die 
Entwicklung eines Impfstoffes gegen Krebs liefern. 
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Summary 
Structural analysis of Yersinia pyruvate kinases reveals the basis 
of allosteric regulation 
Foodborne diseases are becoming more prevalent recently. Yersinia enterocolitica is one of 
the pathogenic bacteria that cause the foodborne disease called yersiniosis. The study on the 
Yersinia enterocolitica’s metabolic system would be a good strategy to control the infection. 
Pyruvate kinase, which is one of the glycolytic enzymes, is highly regulated and plays an 
important role in controlling the metabolic flux. Yersinia has two types of pyruvate kinases, 
YePykF and YePykA, which are allosterically regulated by fructose 1, 6-bisphosphate 
(F16BP) and AMP, respectively. Non-tagged Yersinia pyruvate kinases (PK) YePykF and 
YePykA were expressed and purified from E. coli expression system. Both PKs were 
crystallized alone and also co-crystallized with their allosteric effectors. The X-ray structures 
of Yersinia PKs revealed architectures similar to the other already reported pyruvate kinases. 
The comparison between YePykF and YePykF+FBP complex structures revealed 
conformational changes on both allosteric site and active site. Upon F16BP binding, a loop 
region in allosteric site changes its conformation, and the B domain rotates towards the A 
domain by 14.6° on average leading to a partial closure of the active site. YePykA structure 
was solved only in complex with AMP. Due to the low quality of the dataset, the AMP 
binding site remains unclear. 
Towards structural elucidation of hepatitis C virus (HCV) - host 
receptor interactions 
Hepatitis C virus (HCV) is the major causative pathogen of acute and chronic liver diseases, 
liver cirrhosis, hepatocellular carcinoma and liver failure. Approximately 160 million people 
are infected worldwide, with an estimated 130 million chronically infected. No vaccine is 
available and current therapies are effective against most genotypes but not all. HCV host cell 
entry requires numerous factors cooperating in a temporally and spatially ordered manner. 
The interaction between HCV envelope protein E2 and a scavenger receptor class B type I 
(SRB1) is considered necessary in the virus entry process. The structural analysis of E2 and 
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SRB1 would provide valuable information for blocking the virus entry and hence control of 
the HCV infection. Both E2 and SRB1’s extracellular domains were cloned and expressed 
from different eukaryotic expression systems. The proteins transiently expressed with HEK 
293 cells showed high aggregation due to misfolding. Later HCV sE2 was homogenously 
expressed from CHO lec 3.8.2.1 stable cell line. The purified sE2 was set up for 
crystallization, but no crystals were obtained. Around the same time of these experiments, 
two E2 core structures without hypervariable regions were published. SRB1 ectodomain was 
homogenously expressed from insect cells, leading to protein of high purity. Due to unknown 
reason, these results were not reproducible. 
Exploration of the legumain autoactivation process 
The cysteine protease legumain turned out to be a byproduct of HCV sE2 purification. CHO 
lec 3.8.2.1 is constitutively secreting prolegumain to the cell culture medium. Legumain is 
considered to be an asparaginyl endopeptidase because it specifically cleaves after asparagine 
at pH 5.8. Mammalian legumain is considered to function in immunity, signal transduction, 
bone resorption and tumor growth/metastasis. Two prolegumain and one active legumain 
structures have been solved in this work. The tertiary structure of prolegumain has three 
domains: the C-terminal legumain stabilization and activity modulation (LSAM) domain; the 
pH-activated legumain (AEP) and an activation peptide (AP). During pH shift from neutral to 
acidic, prolegumain can be cleaved at two cleavage sites, causing the release of the AP 
peptide and C-terminal LSAM domain, and leading to an active legumain. The high-
resolution active legumain structure reveals a succinimide residue in the active site. The 
succinimide is cyclized from an aspartate residue, and not related to protein degradation. 
Although crystallization plates have been set up with active legumain, two crystal forms 
show the prolegumain architecture, in which the cleaved domains are held together but not 
ligated. The re-ligation of peptide bonds in vitro has been reported by others. The structural 
study on legumain would provide valuable information for drug design and cancer vaccine 
development. 
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I.1 Introduction 
I.1.1 Infection 
Infection is the invasion and multiplication of pathogenic microorganisms in a host 
organism’s body tissues, especially that causing local cellular injury by competitive 
metabolism, toxins, intracellular replication, or antigen-antibody response (Dorland’s 
Medical Dictionary for Health Consumers, 2007). The infectious process involves several 
factors, and occurs only if each factor is present in a proper sequence. This involves an 
infectious agent, a reservoir in which the microbes can survive, a portal of exit to get out of 
the reservoir, a mode of transmission by an intermediate object, a portal of entry to get into a 
new reservoir and a susceptible host who is unable to resist infection forming a nonreversible 
chain of infection (Figure I.1). If any link in the chain can be broken, the infection won’t 
spread further.  
Figure I.1: Chain of Infection. Schematic of the chain of infection according to 
http://contagions.wordpress.com/2010/11/06/what-is-the-chain-of-infection/.  
Infectious Agents 
Bacteria, viruses, Fungi, 
Parasites 
Reservior 
Human beings, Animals, 
Inanimate objects 
Portal of Exit 
Blood, Intestinal tract, 
Mucous membrane, Cut 
skin, Respiratory tract 
Mode of Transmission 
Airborne, Contact, Vector 
Portal of Entry 
Blood, Intestinal tract, 
Mucous membrane, Cut 
skin, Respiratory tract 
Susceptible Host  
Age, Health status 
Chain of Infection 
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Infectious agents also called pathogens are microorganisms that include bacteria, viruses, 
fungi, protozoa and others. Pathogens vary in infectivity and virulence, with differences 
depending on different architecture of the pathogens and the virulence factors they produced. 
For initiating a disease, an infectious dose (a sufficient number of pathogens) is also required.  
I.1.2 Bacterial infection 
Bacterial infection is any type of infection that is caused by pathogenic bacteria. Our bodies 
contain billions of bacteria, the mass of which is estimated to account for 1-3% of the body 
weight (MacDougall, 2012). Most bacteria are harmless or even beneficial and are called 
normal flora. The normal flora can help digesting food, sustaining normal pH of the body, 
and providing essential nutrients. The normal flora does not cause disease unless the balance 
is disturbed or the normal living place of the bacteria changed (Yonath, 2004). The World 
Health Organisation (WHO) reported emerging foodborne diseases were caused by bacterial 
pathogens (WHO, Fact sheet N
o
 124). Pathogenic bacteria that cause these diseases include 
Yersinia enterocolitica, Salmonella spp., Vibrio cholerae, Listeria monocytogenes and 
pathogenic E. coli.  Foodborne diseases are becoming more prevalent for several reasons that 
include increasing international travel and trade, the storage of large amounts of frozen food, 
and most importantly, the rise in pathogen resistance against antibiotics.  
I.1.3 Yersinia infection 
The genus Yersinia belongs to the family Enterobacteriaceae. These are Gram-negative rod 
shaped, and facultative anaerobic bacteria. So far, 17 species have been reported in this genus, 
but only three species are pathogenic for human beings. These are Yersinia pestis, Yesinia 
pseudotuberculosis and Yersinia enterocolitica [European Food Safety Authority (EFSA), 
2013]. 
Yersinia enterocolitica and Yersinia pseudotuberculosis are the most common pathogens of 
foodborne diseases, which cause the disease called yersiniosis [ECDC Annual 
epidemiological report (2011)]. In 2011, 7041 confirmed cases of yersiniosis were reported in 
European countries, with an overall proportion of 2.19 per 100000 persons. In the past, 
Germany accounted for the highest proportion of 47.9% of all reported cases. Yersinia 
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enterocolitica was the main species in human reported cases (98.4% of all confirmed cases in 
2011). Many cases are considered to be associated with the ingestion of uncooked pork 
(ECDC annual epidemiological report, 2013). After ingestion via contaminated food or water, 
the enteropathogenic Yersinia pass through the intestinal tract and reach the terminal ileum, 
where they can bind to the microfold cells (M cells) of the small intestine. Via a plasmid 
encoded Type III secretion system Yersinia translocate anti-phagocytic proteins (Yops) into 
the macrophages and induces apoptosis. The bacteria are released and then may disseminate 
to mesenteric lymph nodes or even deeper tissues such as the liver and spleen (Figure I.2). 
Common symptoms are fever, abdominal pain, and diarrhea, which is often bloody (Bottone, 
1997). The diagnosis is usually confused with appendicitis.  Symptoms occur four to seven 
days after exposure to the infectious pathogen, and usually last for 1 to 3 weeks or longer. 
Treatment usually requires aggressive antibiotics that include ciprofloxacin, chloramphenicol, 
ampicillin, and polymyxin (https://en.wikipedia.org/wiki/Yersiniosis). More than 50% of 
Yersinia enterocolitica infections occur in children younger than five, and about 38% of all 
infections occur in infants less than one year old. Infections in infants are more dangerous 
and might develop into bacteremia, where bacteria are present in the blood stream and 
usually fatal (Bent et al., 2013). 
 
Figure I.2 Infection route of enteropathogenic Yersinia species. Figure was drawn according to Sansonetti, P. 
(2002). 
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After exposure to host cells, Yersinia enterocolitica initiates infection through a protein 
export apparatus called the Type III secretion system (T3SS) or an injectisome. Several well-
known Gram-negative bacterial pathogens, including Shigella flexneri, Pseudomonas 
aeruginosa, Salmonella typhimurium and Yersinia use this system.  There are two types of 
Type III secretion systems (T3SS) present in Yersinia enterocolitica biovar 1B, the plasmid 
encoded Ysc T3SS and the chromosomally encoded Ysa T3SS. The Ysa T3SS was reported 
to be only been expressed at 26 ℃ in a high nutrient medium with a high concentration of 
salt (Bent et al., 2013).  The injectisome is composed of ~25 proteins and facilitates the 
bacteria to attach to the cell membrane and to inject effector proteins through this membrane 
into host cells (Cornelis, 2006). Recent studies combining electron microscopy (EM), X-ray 
crystallography, and nuclear magnetic resonance (NMR) spectroscopy revealed amazingly 
detailed models of the injectisome. The injectisome can be divided into 3 parts: a hollow, 
~60nm long needle protruding from the bacteria surface, a basal body that spans through two 
bacteria membranes and the periplasm, and a cytoplasmic part (Figure I.3). The basal body is 
formed by three multimeric proteins (YscC, D, J in Yersinia spp). YscC secretin forms a 12-
15mer barrel-shaped structure that spans the OM and protrudes into the periplasm (Burghout 
et al., 2004; Hodgkinson et al., 2009; Schraidt and Marlovits, 2011; Spreter et al., 2009). 
YscJ is a lipoprotein and was proposed to form a 24-subunit ring, which reaches into the 
inner membrane (Hodgkinson et al., 2009; Silva-Herzog et al., 2008). Ysc has an elastic 
structure and acts as a connector between the secretin and the IM (Diepold et al., 2010). 
According to our collaborators from RKI (Robert Koch Institute), two secreted YscM 
proteins (YscM1 and YscM2) of T3SS are assumed to interact with pyruvate kinases and 
activate them. The interaction is not only with Yersinia PK but also with the PK from host 
cells. The assumption is that the interaction between YscM and PKs could activate PK and 
provide more energy to facilitate infection and more metabolites for bacteria grow, and at the 
same time, disturb the metabolic system of host cells.  In this work, the interaction between 
YscM and PKs has been explored, but haven’t been quantified to a stoichiometry level in 
vitro. 
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Figure I.3: Structure of the Y. enterocolitica injectisome in situ. Slice through the average 3D structure of the 
injectisome and a model with components. OM–outer membrane, PL–peptidoglycan layers, IM–inner 
membrane。* indicates the junction between YscC and YscD (Kudryashev et al., 2013). 
I.1.4 Pyruvate kinase 
Pyruvate kinase (ATP: pyruvate 2-O-phosphotransferase (EC 2.7.1.40); PK) catalyzes the last 
step of glycolysis, where a phosphoryl group is transferred from phosphoenolpyruvate (PEP) 
to ADP to yield pyruvate and ATP (Valentini et al., 2000). The PK catalyzes the reaction in 
two steps (Figure I.4). The first step, a phosphoryl group is transferred from PEP to ADP, 
forming an enolate intermediate and yielding an ATP molecule; in a second step the Thr328 
and the Mg
2+
 cation increase the acidity of water through hydrogen bonding and charge 
stabilization, respectively. A specific acid is generated to act on the enolate intermediate 
causing the protonated enolate intermediate to tautomerize to pyruvate. A hydroxide is 
produced and can be reprotonated back to the original state (Dombrauckas et al., 2005). 
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Figure I.4: The reaction mechanism of pyruvate kinase catalyzed reaction. The reaction takes place in two 
steps. (a) Step 1: the transfer of a phosphate group from PEP to ADP, and the formation of an enolate 
intermediate. (b) Proposed hydrogen-bonding scheme through a water molecule, which is responsible for the 
protonation of enolate.  Protonated enolate intermediate tautomerizes to pyruvate and a hydroxide is yielded. 
Adopted from Dombrauckas et al. (2005).  
PK catalyzes one of the two steps producing ATP in glycolysis. Under physiological 
conditions, the reaction is irreversible and highly favored because the energy released from 
the transition of PEP to pyruvate (∆GPEP = 58 kJ/mol) is much higher than the synthesis of 
ATP (∆GATP = 29 kJ/mol) (Dombrauckas et al., 2005). PK requires monovalent K
+
 and 
divalent Mg
2+
 or Mn
2+
 cations for its activity (Mattevi et al., 1995). The substrate PEP and 
product pyruvate are involved in a number of metabolic pathways. As most enzymes of 
glycolysis, PKs are highly regulated by many different chemicals and play an important role 
in controlling the metabolic flux. It serves as a switch between the glycolytic and the 
gluconeogenic pathways, and the glycolytic phospho-metabolites are used as synthetic 
precursors in cellular proliferation (Bakszt et al., 2010; Mazurek et al., 2005). 
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Bacteria typically harbor a single type of PK enzyme. However, a few bacteria, such as 
Escherichia coli, Salmonella and Yersinia, harbor two types of PK isozymes (type I and type 
II pyruvate kinases). Both PK isozymes can be activated by their substrate PEP and inhibited 
by the product ATP, which is called homotropic activation. However, both PK isozymes can 
also be activated by their effectors that bind to different position in the active site, which is 
called heterotropic activation. The type I pyruvate kinase (PykF) is usually activated by 
fructose 1, 6-diphosphate (F16BP) or fructose 2, 6-diphosphate (F26BP). The type II 
pyruvate kinase (PykA) is usually activated by AMP and monophosphorylated sugars (i.e. 
ribose-5-phosphate) (Hofmann et al., 2013).  
In eukaryotes, most PKs resemble the prokaryotic type I isozyme. They are allosterically 
activated by F16BP or F26BP. In mammals, there are four PK isozymes that are expressed in 
different tissues or in different life stages. PKL exists in liver, PKR in red blood cells, PKM1 
is present in normal differentiated tissues, and PKM2 is found in embryonic cells and other 
proliferating cells, such as cancer and tumor cells. PKL, PKR and PKM2 isozymes are 
allosterically regulated by F16BP and PKM1 is constitutively active (Dombrauckas et al., 
2005). In mammals, some hereditary diseases are related to mutations of PKs. The most 
famous one is the hereditary nonspherocytic hemolytic anemia, which is caused by PK 
deficiency in erythrocytes. Over 130 mutations are known that lead to a lowered production, 
activity, or stability of PKR. A complete knock out of this enzyme is usually lethal. In severe 
cases it can be life threating, and the patients might need regular blood transfusions to survive. 
A transgenic rescue strategy is still ongoing (Kanno et al., 2007).  
PKs play an especially important role in certain cancer cells. Tumors occur when cells divide 
and grow excessively in the body. Oxygen in the tumor microenvironment is consumed and 
an anaerobic microenvironment is formed. Tumors without sufficient supply of oxygen rely 
heavily on ATP produced via the glycolytic cycle and hence on the activity of PKs 
(Dombrauckas et al., 2005).  There is a strong correlation between the up-regulation of 
human PKM2 and incogenesis, and PKM2 is found in all tumors studied so far (Christofk et 
al., 2008). In contrast, inhibition of PK activity was shown to be beneficial for certain types 
of cancer cells as it leads to an increased availability of glycolytic metabolites that are 
necessary for tumor growth (Anastasiou et al., 2012). The decision whether glucose is 
converted to lactate for maximized production of ATP or used for the synthesis of cellular 
building blocks is made at the level of PKs, and regulation of PK activity is crucial for tumor 
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cells to maintain the fine balance between these two opposing requirements (Mazurek, 2011). 
Hence the regulation of PKs activity might be a strategy for cancer treatment. Potential ways 
to achieve this could be through the use of small molecules that act as allosteric 
activators/inhibitors of PKs or the induction of oxidative stress as this is known to lead to PK 
dissociation and inactivation (Mazurek, 2011).  
I.1.4.1 Architecture of pyruvate kinases 
The first PK structure has been reported in 1975 (Stuart et al., 1979, Stammers and Muirhead, 
1975). Since then, 67 Structures of PK from 14 species (with pairwise sequence identities as 
low as 24%) have been elucidated in complex with various ligands, and the investigation is 
still ongoing. PKs have been extensively characterized in Leishmania mexicana, 
Trypanosoma brucei, Felis catus (Cat) and Homo sapiens (Human). The common 
characteristics of these enzymes are the subunit is around 50 kDa and the oligomeric state is 
either T or R-state tetramer. For bacterial phosphofructokinase, the T-state means tense state 
and is usually the inactive state, while the R-state means the relaxed state, and is usually the 
active state (Perutz, 1989). For convenience, we retain the nomenclature of T-state and R-
state to be inactive and active states, respectively.  
Every PK subunit has four domains. The first 50 amino acids form an N-terminal domain, 
which is usually a helix-loop-helix motif, or only one helix in some pyruvate kinases. The N-
terminal domain is only present in eukaryotic cells and is absent in prokaryotic cells (Rigden 
et al., 1999). The A domain, composed of an (α/β)8 barrel, forms the rigid body of PK. The C 
domain, usually composed of α and β elements, is the effector binding domain, while the B 
domain, composed of β-strands and random coils, is usually flexible (Bakszt et al., 2010). 
The active site is located in a pocket between the A and B domains. Two kinds of interfaces 
are indicated with green and black dashed lines in Figure I.5. Two subunits form an 
asymmetric dimer through an adjacent A-domain interface and is called the “large” interface. 
The tetramer structure formed through an adjacent C-domain interface is called the “small” 
interface. The PK homotetramer, consisting of a dimer of dimers, forms a ring in which the B 
domains behave like mobile lids covering both ends of the ring (Figure I.5) (Tadesse et al., 
2013).  
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Figure I.5: Structure of the LmPYK·ATP·OX·Fru-2, 6-BP complex showing domain boundaries and 
tetramer architecture (Morgan et al., 2010). (a) LmPYK·ATP·OX·Fru-2,6-BP tetramer highlighting the active, 
effector, and potassium (K
+
) sites. The large and small interfaces between monomers are shown as dashed lines. 
(b) LmPYK·ATP·OX·Fru-2, 6-BP tetramer in which one subunit has been colored to show domains; N domain 
(green, residues 1–17), A domain (yellow, residues 18–88 and 187-356), B domain (blue, residues 89–186), and 
C domain (red, residues 358–498). 
Although PKs have many characteristics in common, there are structural differences between 
different species. These differences have been explored and targeted in research for anti-
infectious diseases caused by bacteria and parasites (Nowicki et al., 2008; Zoraghi et al., 
2011a; Zoraghi et al., 2011b). Bis-indole alkaloids and IS-130 have been found to be 
effective inhibitor for methicillin resistant Staphylococcus aureus PK. These chemicals have 
been explored in antibacterial drug research (Axerio-Cilies et al., 2012; Zoraghi et al., 2011b). 
Chemicals like suramin (Tadesse et al., 2013), 4-[(1,1-dioxo-1,2-benzothiazol-3-yl) sulfanyl] 
benzoic acid (DBS) (Morgan et al., 2012) have been found to work as inhibitors of 
Leishmania Mexicana PK and have been utilized in anti-parasitic research. 
I.1.4.2 Yersinia enterocolitica pyruvate kinases 
Yersinia enterobacteriaceae harbor both isozymes YePykF and YePykA. YePykF has 470 
amino acids with a molecular weight of 50.5 kDa, and is allosterically regulated by F16BP. 
  Chapter I: Structural analysis of Yersinia pyruvate kinases reveals the allosteric strategy 
17 
YePykA has 480 amino acids with a molecular weight of 51.5 kDa, and is allosterically 
regulated by AMP and ribose-5 phosphate. The sequence identity of YePykF and YePykA is 
36.7% (Figure I.6) and the enzymatic activity of YePykF is higher than that of YePykA 
(Hofmann et al., 2013). 
 
Figure I.6: Amino acid sequence alignment of YePykA and YePykF. Identical residues are highlighted in 
red, similar residues are surrounded by a blue box.  
I.2 Aim of the work 
This project is aimed at elucidating the allosteric effect of PK by effector binding. The 
investigation of the regulation mechanism of PKs will provide information about the effects 
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of disturbing the balance between energy production and metabolites production of tumor 
cells, thus providing insights for drug design in cancer treatment. Another aim is to explore 
the activation mechanism between PK and YscM to further explain the Yersinia infection 
mechanism.  
I.3 Results  
I.3.1 Purification of pyruvate kinase YePykF and YePykA  
YePykF and YePykA of Yersinia enterocolitica WA-314 were cloned into a IPTG-inducible 
pWS vector. Non-tagged YePykF and YePykA were recombinantly expressed in Escherichia 
coli BL21 (DE3) pLysS competent cells. Both proteins have higher solubility when expressed 
in 300 K than in 310 K. Larger scale protein production was done by adding 0.1 mM IPTG in 
2YT medium at 300 K for 5 hours. Both proteins were purified by combining anion exchange 
chromatography on a HiPrep16/10 Q XL column and size exclusion chromatography on a 
Superdex 200 prep grade column. Elutions of YePykF and YePykA from size exclusion 
chromatography were in accordance with the formation of protein tetramers. Unusually 
YePykF (50.5 kDa) was eluted significantly and reproducibly before YePykA (51.5 kDa) 
with a peak at 171 ml compared to 176 ml for YePykA. This could be explained by 
unspecific interaction of YePykA with the Superdex matrix that delays the elution. The yields 
for YePykF and YePykA were approx. 183 mg/L and 250 mg/L respectively. The specific 
activities determined by Dr. Julia Hofmann (Robert Koch Institute) for YePykF and YePykA 
(108 U/mg and 85 U/mg) are consistent with other pyruvate kinases (Hofmann et al., 2013; 
Zoraghi et al., 2010).  
Protein samples with 10% glycerol have been stored at 193 K for crystallization tests. Before 
each crystallization test, one frozen protein fraction (10mg) was thawed on ice. Re-
purification was performed with anion exchange chromatography on a MonoQ 5/50 GL 
column and size exclusion chromatography on a Superdex 200 HR 10/30 column. The aim of 
the re-purification was to remove the putative inhomogeneity that might have arisen during 
freezing and thawing, and hence increase the protein’s propensity for crystallization. YePykF 
and YePykA show similar behavior in their size exclusion chromatography profile. YePykF 
and YePykA both eluted around 10 - 15 mL, which corresponds to the size of a protein 
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tetramer. SDS-PAGE analysis showed protein bands at about 51.5 kDa for YePykA and 50.5 
kDa for YePykF, with purity above 98% (Figure I.7 and Figure I.8). Although YePykF and 
YePykA have identical molecular weights but differ in their pI values. YePykF has a pI value 
of 6.0, while YePykA has a pI value of 6.8.  Accordingly, in anion exchange chromatography, 
YePykF eluted earlier (44 ml, 23% conductivity) than YePykA (45 ml, 25% conductivity). 
 
Figure I.7: Chromatograms of the YePykF purification monitored at λ = 280 nm, and SDS-PAGE of size 
exclusion peak fractions. (A) Chromatograms of YePykF MonoQ 5/50 QL anion exchange Chromatography. 
The blue curve indicates UV absorbance, and the cyan curve indicates the conductivity. (B) Chromatograms of 
YePykF on Superdex 200 10/30 column. Coomassie-stained SDS-PAGE containing every peak-fraction of the 
YePykF gel filtration, the fraction size is 1ml. MW: Molecular weight marker.  
 
Figure I.8: Chromatograms of the YePykA purification monitored at λ = 280 nm, and SDS-PAGE of size 
exclusion peak fractions. (A) Chromatograms of YePykA MonoQ 5/50 QL anion exchange Chromatography. 
The blue curve indicates UV absorbance, and the cyan curve indicates the conductivity. (B) Chromatograms of 
YePykA on Superdex 200 10/30 column and SDS-PAGE of peak fractions. Coomassie-stained SDS-PAGE 
showing peak-fractions of the YePykA gel filtration run. The fraction size is 1ml. MW: Unstained low 
molecular weight marker.  
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Thermoshift assay, also called Differential Scanning Fluorimetry (DSF), measures the thermo 
stability of proteins and protein-ligand complexes using a fluorescent protein binding dye. 
The assay usually includes a buffer screen and an extra additive screen. The protein stability 
changes with buffer pH, salt content and cofactors. The first step buffer screen identified a 
buffer (10 mM Tris, pH 8.0, 100 mM KCl) where YePykF and YePykA were most stable. The 
second step was based on the buffer condition that confirmed and tested different additives 
that might stabilize the proteins. YePykF and YePykA were analyzed by thermal shift assay 
with five different ligands for each. SYPRO orange was employed as fluorescence signal for 
its non-specific binding ability to a protein hydrophobic surface (Kranz and Schalk-Hihi, 
2011; Niesen et al., 2007). YePykF was tested with pyruvate, oxalate, PEP, ADP and F16BP. 
YePykA was tested with pyruvate, oxalate, PEP, ribose 5-phosphate and AMP. Each 50µl 
testing system includes 0.5 mg/ml YePykF or YePykA protein, 5 mM of the test ligand. In 
negative controls, no ligand was added. The plate was slowly heated up from 283 K to 363 K 
in 0.5 K increments. The excitation and emission wavelengths were 485 and 575 nm, 
respectively. The fluorescence signal was analyzed with the CFX Manager software and 
interpreted as melt curves. F16BP had the greatest impact on the melting temperature of 
YePykF, increasing it by 12 K, from 319 K 331 K (Figure I.9). For PykA, AMP binding 
yielded the largest melt temperature jump from 319 K to 328 K. This melting temperature 
shift indicates the improvement of protein thermo stability by ligand binding. Even further, 
we could speculate the conformational change of free protein from a loose state to a tight 
state after ligand binding. 
 
Figure I.9: Thermo shift assay for YePykF and YePykA. Curves with different numbers indicate the 
different ligands tested. (a) YePykF with different ligands. 1: No ligand; 2: 5 mM pyruvate; 3: 5mM oxalate; 4: 
5mM PEP; 5: 5mM ADP; 6: 5mM F16BP; C: buffer control. (b) YePykA with different ligands. 1: No ligand; 2: 
5 mM pyruvate; 3: 5 mM oxalate; 4: 5 mM PEP; 5: 5 mM ribose 5-phosphate; 6: 5 mM AMP; C: buffer control. 
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To analyze the secondary structure of YePykF and YePykA, circular dichroism (CD) 
spectroscopy was employed. CD spectroscopy is a technique where the CD of molecules is 
measured over a range of wavelengths. It is extensively used to study chiral molecules of all 
types and sizes, but it is mostly useful in studying larger biological molecules. The CD 
spectra exhibited two minima around 208 nm and 222 nm, which is a typical indication of an 
α-helical conformation. Recorded CD spectra illustrate minor differences between YePykA 
and YePykF and confirm their overall high content of α-helices. In the presence of the known 
allosteric activator F16BP, the CD spectrum of YePykF was only marginally changed (Figure 
I.10). This indicates that F16BP binding didn’t change the secondary structure content of 
YePykF, the conformational change might be rigid body domain movement. 
 
Figure I.10: Structural prediction of PykA and PykF by CD spectroscopy. The far-UV spectra of YePykA 
(22 µM), YePykF (10 µM) and YePykF+F16BP (YePykF: 9 µM; F16BP: 10 mM) were recorded in 20mM 
Tris-HCl (pH 8.0) at 283 K using a path length of 1 mm.   
I.3.2 Crystallization of YePykF, YePykF+FBP and YePykA 
Crystallization tests of purified YePykF and YePykA were set up with the sitting drop vapor 
diffusion method. Protein and reservoir volume ratio was set to 1:1 (0.2 μl : 0.2 μl) with a 
total volume of 0.4 μl. 496 different crystallization conditions were carried out with different 
protein concentrations (5-10 mg/ml). Although the protein is stable at higher concentrations, 
crystallization at ≥10 mg/ml led to too many tiny crystals, and ≤ 5mg/ml yielded irregular 
shaped crystals. Hence, 8 mg/ml of protein was used as a standard for crystallization 
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experiments. The crystallization temperature was varied from 277 K to 293 K (277 K, 285 K, 
293 K). YePykF can be stabilized by F16BP, and YePykA can be stabilized by AMP. In 
order to elucidate the conformation differences between proteins and protein-effector 
complexes, co-crystallization experiments including their effectors was also performed. 
Three dimensional crystals of PykF+F16BP complex crystallized in conditions consisting of 
19-25% PEG 6000, 0.2M Tris/HCl, pH 7.6, 0.1M KCl at 293 K. Small three dimensional 
crystals were observed under the microscope 2-3 hours after the setup of the drop and were 
tested for X-ray diffraction after 2-3 days (Figure I.11 C and D). Crystal quality was 
improved by iterative fine screens matrix micro seeding. The best quality crystals were 
obtained from a condition containing 18% PEG 6000, 0.2M Tris/HCl, pH 7.6, 0.1M KCl at 
293 K, with a crystal length of 0.8 mm.  In contrast, YePykF did not yield any crystal over 
the same time period.  
Lenticular crystals (Figure I.11 A and B) of YePykF have been obtained from initial screens 
6 months after screens were set up at 285 K. The condition contains 1.6 - 2 M ammonium 
sulfate, 0.1 M Tris/HCl, pH 8.0. The largest crystal has a length of 50 μm, which is much 
smaller, compare to 0.8 mm of the largest YePykF+FBP crystal. Since the crystallization 
process was too long, no optimization was performed. Single crystal was fished and cryo-
protected with ammonium sulfate as a cryo-protectant.  
Non-tagged YePykA was expressed and purified similar to YeykF. In the initial screens, 
many needle crystals of YePykA and YePykA+AMP were obtained under different 
conditions. However, these crystals showed no diffraction in X-ray diffraction experiments. 
Even after several rounds of optimization, their quality did not improve. There was only one 
condition from a Midas screen, containing pentaerythritol ethoxylate (15/4 EO/OH) as a 
precipitant, that yielded three-dimensional crystals for YePykA+AMP (Figure I.11 E and F). 
Pentaerythritol ethoxylate is a branched polymer built on a pentaerythritol backbone. It forms 
branched polymers and behaves differently from traditional precipitants like MPD and PEGs 
in size and characteristics. In addition, pentaerythritol ethoxylate polymers also function as 
cryoprotectant. Crystals grown in a high concentration of this precipitant can be cryo-
protected and frozen directly from the crystallization drop (Gulick et al., 2002). After several 
rounds of fine screens and seeding by the hanging drop method, the best crystal diffracted to 
3.3 Å resolution, which allowed us to solve the YePykA+AMP structure. The X-ray data 
collection and refinement statistics are shown in Table II.1. These crystals are only from 
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YePykA in complex with AMP. For YePykA alone, only tiny crystals were obtained, which 
did not diffract to better than 5 Å, leaving the apo YePykA structure still unsolved. 
 
Figure I.11: Crystals of Yersinia pyruvate kinases. A and B: Lenticular crystals of YePykF; C and D: Three 
dimensional crystals of YePykF+F16BP; E and F: three-dimensional crystals of YePykA. 
I.3.3 Data collection, model building of YePykF and YePykF+FBP and YePykA+AMP 
Complete X-ray diffraction data of all three forms of crystals were collected using 
synchrotron radiation. Crystals of YePykF+FBP diffracted to 1.9 Å at the beamline 14.2 of 
BESSY II, Berlin, Germany. The data were processed by the XDS package in space group 
C121. From sequence alignment result, E.coli PykF has the highest sequence identity (85.7 %) 
with YePykF in the available PDB entries. E.coli PykF (1E0T) was chosen as search model 
for molecular replacement. Guided by a sequence alignment of YePykF and E.coli PykF, the 
program CHAINSAW (CCP4, 1994) was used to trim the search model at non-conserved 
positions.  Matthew’s coefficient (Vm = 2.56) revealed there are two molecules per 
asymmetric unit, and the solvent content is 51.9 %. Based on Vm, Phaser statistics indicated 
a very high probability of this solution being correct with a log likelihood gain of 3067.  
Similar to the other reported PK structures, the B domain of YePykF+FBP was also found to 
be out of electron density. The initial model quality was improved by manual building of B 
domain in Coot and refinement in Phenix.refine. After inclusion of effector atoms (F16BP) 
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and water molecules, an R factor value of 19.1% and Rfree value of 22.4% were reached, 
which is in a good agreement with the resolution of 1.9 Å.  
YePykF crystals diffracted X-ray to 2.7 Å using synchrotron radiation at the beamline P11 of 
PETRA III, Hamburg, Germany. Initial indexing revealed a hexagonal symmetry with unit 
cell dimensions of a = b = 263.75 Å and a short c axis of 101.29 Å. The data were processed 
by XDS with a space group P622, which contains two possible space groups P6422 and P6222. 
Initially, molecular replacement was done against PykF+FBP structure, but the B domain 
didn’t fit into the electron density. During structure building, the B domain was found to 
move as a rigid body. Thus the B domain was separated from the YePykF+FBP structure as 
an ensemble. Molecular replacement was done against 2 ensembles from the PykF+FBP 
structure: B domain (residues 71 - 167) and AC domain (residue 1 - 70 and residue 168 - 
470). The calculation of a Phaser_MR self-rotation function, taking into account all screw 
axes, revealed P6222 as the correct space group, with a log likelihood gain of 10385 and the 
translation function Z-score of 30.3. Matthew’s coefficient (Vm = 2.52) indicated two 
molecules per asymmetric unit and the solvent content was 51.2 %. After manual building in 
Coot and refinement with REFMAC5, the structure model of YePykF was improved with an 
R factor value of 18.4% and Rfree value of 21.5%.  
X-ray diffraction data of crystals from PykA+AMP were also collected using synchrotron 
radiation at the beamline P11 of PETRA III, Hamburg, Germany. The crystals diffract beyond 
3.1 Å but the dataset could only be scaled to 3.3 Å due to anisotropic problems. The indexing and 
integration was carried out with the XDS package (Kabsch, 2010). These crystals have a very 
high Wilson B-factor of 102.4 Å2, whereas the average values of the PDB structures with 
similar resolutions is 65.25 Å2 for 3.25 - 3.5 Å resolution. The Matthew’s coefficient (Vm = 
2.47) indicated four molecules per asymmetric unit with a solvent content of 50.3 % 
(Matthews, 1968). Initial indexing revealed a P321 space group, which has three alternative 
space groups P321, P3221 and P3121. Calculation of the Phaser_MR self-rotation function 
solved the space group as P3221. Based on sequence alignment and the available PK structure 
models, YePykF+FBP was used as a molecular replacement model. The trimmed model of 
YePykF+F16BP was produced by CHAINSAW and depended on the sequence alignment of 
YePykA and YePykF. Molecular replacement was carried out with Phaser_MR against two 
ensembles from trimmed YePykF+F16BP (B domain and AC domain) with a log likelihood 
gain of 13706 and translation function Z-score of 17.5. Refinement was done by 
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Phenix.refine including refinement of NCS restraints, secondary structure restraints and 
Ramachandran restraints. The final R factor of 24.7% and Rfree of 29.6% were reached. Data 
collection and refinement statistics are summarized in Table I.1.  
Table I.1: Data collection and refinement statistics for YePykF, YePykF+F16BP and YePykA+AMP 
datasets 
Data statistics YePykF YePykF+F16BP YePykA+AMP 
Beamline Petra III, P11 BESSY II, 14.2 Petra III, P11 
Wavelength (Å) 1.033 0.918 1.033 
Space group P 62 2 2 C 1 2 1 P 32 2 1 
Unit cell constants: a, b, c (Å) 263.8, 263.8, 101.3 168.7, 90.0, 68.3 151.0, 151.0, 154.0 
                                α, β, γ (°) 90, 90, 120 90, 94.67, 90 90, 90, 120 
Resolution range (Å) 20.0-2.7 (2.8-2.7) 20.0-1.9 (1.97-1.90) 20.0-3.3 (3.40-3.30) 
I/σ (I) 20.0 (2.3) 13.9 (2.7) 26.6 (2.7) 
Completeness (%) 100.0 (100.0) 96.5 (97.4) 96.8 (98.0) 
Unique reflections 56975 (5602) 77321 (7752) 29956 (2992) 
Multiplicity 2.0 (2.0) 1.8(1.8) 2.0 (2.0) 
Rmerge (%) 28.9 (29.7) 27.8(33.0) 32.0 (32.9) 
Wilson B-factor (Å
2
) 57.04 25.89 102.4 
Solvent content (%) 51.2 51.9 50.3 
Refinement statistics 
Mol. PK / a.s.u. 2 2 4 
Rwork (%) 18.4 (26.1) 19.1 (26.4) 24.7 (51.8) 
Rfree (%) 21.5 (26.5) 22.4 (26.9) 29.6 (54.8) 
av. B-factor of all atoms (Å
2
)  72.4 35.2 107.3 
r.m.s.d. bonds (Å) / angles (°) 0.004/0.83 0.008/1.05 0.010/2.04 
Ramachandran favored (%) 
 
96.1 98 96 
Ramachandran allowed (%) 3.6 1.89 3.34 
(): Values in () stand for the highest resolution shell. 
I.3.4 Overall structure of YePykF and YePykF+FBP  
The type I pyruvate kinase of Yesinia (YePykF) consists of 470 amino acids. Non-tagged 
YePykF gene was recombinant expressed in Escherichia coli BL21 (DE3) pLysS strain. 
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About 98.5% (463 out of 470) and 95.7% (450 out of 470) of the amino acids could be 
interpreted in the electron density of YePykF+FBP and YePykF structures, respectively. Both 
structures have a missing region from Thr345 to Arg350, and the YePykF structure has two 
more missing regions located from Met280 to Asn287 and Ser312 to Lys317. 
YePykF is well structured with mostly α-helices and β-strands, in which the determination of 
secondary structure elements are based on the DSSP algorithm (Kabsch and Sander, 1983). 
YePykF contains 15 α-helices and 21 β-strands (Figure S1). Both the N-terminus and C-
terminus are composed of β-strands and fitted quite well into the electron density. The 
missing region in both structures is interpreted as a big loop region by DSSP. The other two 
missing regions in YePykF are interpreted as small helices, each of which locates between a 
β-strand and a large helix.  
The YePykF tertiary structure can be divided into three distinct domains (Figure I.12 a and b). 
In the middle of each subunit, there is a rigid A domain (residues 1 - 70 and 168 - 341, cyan), 
which is composed of an (α/β) 8 barrel and 3 small extra helices (β1, α1, β2, α2, β3, α3, β12, 
α4, β13, α5’, α5, β14, α6’, α6, β15, α7, β16, α8, α9). On one side of the subunit, there is a B 
domain (residues 71 to 167, green), which is composed mostly of 7 β-strands (β4, β5, β6, β7, 
β8, β9, β10, β11) and random coils. The B domains in the physiological tetramer behave like 
lids covering the A domain, and point to the outside of the homotetramer. On the opposite 
side of B domain, there is a C domain (residues 341 - 460, pink), which has a αβαβαβαββ 
topology formed by 4 α-helixes and 5 β-strands (α10, β17, α11, β18, α12, β19, α13, β20, β21). 
C domains from 4 subunits assemble in the middle of homotetramer, and are responsible for 
forming of the homotetramer. The catalytic site (active site, violet) is located in a cleft 
between the B and A domains, in which α6’ is critical for the activity. The allosteric effector-
binding site is located in a concave of C domain (yellow orange). The effector-binding 
involves three loops, which are located between α9 and α10, β17 and α11, β20 and β21. 
Detailed interaction between the effector molecule and the YePykF will be shown in section 
I.3.5. 
The quaternary structures of both YePykF and YePykF+FBP are tetramers (Figure I.12 c). 
The tetramer organization has already been confirmed by size exclusion chromatography. 
Both structures have an asymmetric unit as homodimer and the physiological unit as 
homotetramer. The homodimer and homotetramer form through interactions of residues on 
the interfaces. The homodimer was formed through interactions of residues on adjacent A 
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domains (large interface, indicated as blue dashed line). The homotetramer was formed by 
dimerization of homodimers, through the interactions of residues on adjacent C domains 
(small interface, indicated as green dashed line). Four chains of homotetramer adopt almost 
the same conformation. 
The YePykF and YePykF+FBP structures form tetramers through interactions of adjacent 
subunits between A and C domains. Bordering A domains form A-A or the “large” 
interface, while adjacent C domains constitute C-C or the “small” interface. In 
Leishmania Mexicana, the transition of PK from inactive T-state to active R-state undergoes 
a symmetrical 6° rigid-body rotation of each of the four subunits. The transition also involves 
the formation of 8 salt bridges on the small interface (Morgan et al., 2010; Zoraghi et al., 
2011b). Based on the structural differences of the small interfaces of methicillin-resistant 
Staphylococcus aureus (MRSA) PK and mammalian orthologs, a series of natural products 
was selected with antibacterial function (Zoraghi et al., 2011b). Some activators of human 
PKM2 bind in a pocket on the large interface but not to the allosteric site, and promote the 
association of PKM2 subunits into stable tetramers (Anastasiou et al., 2012). Therefore the 
investigation of the interface interaction of YePykF is really necessary to provide information 
for drug development.  
In the YePykF+FBP asymmetric unit, homodimer forms through interactions of residues on 
the lager interface (between monomers A and B, or monomers C and D). Three α-helices (α6, 
Arg244-Lys272; α7, Asn291-Gly305; α9, Gly318-Asp336) from chain A and the 
corresponding three helices from chain B are involved in this interaction (Figure I.13 a). To 
analyze the dimer and tetramer assembly, the PDBePISA web server 
(https://www.ebi.ac.uk/pdbe/pisa) was used. PISA suggests that the large interface plays an 
auxiliary role in dimer formation. In the YePykF large interface, one salt bridge and 16 
hydrogen bonds are formed between monomer A and B, 30 residues from each monomer are 
involved. The interface area is 1112 Å2 for monomers A and B on average. In YePykF+FBP 
structure these interactions increased to 8 salt bridges and 17 hydrogen bonds between 39 
residues from monomers A and B, 39 residues from each monomer are involved. The 
interface area is 1455 Å2 for monomers A and B on average, which is 343 Å2 larger than 
YePykF (Table II.2). The solvent free energy gain on interface formation of YePykF+FBP 
(ΔiG = -13.8 kcal/mol) is also higher than that of YePykF (ΔiG = -12.6 kcal/mol). The 
increased number of interactions and interface areas, and also the free energy gain in the 
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YePykF+FBP structure indicate tighter interaction between two molecules in the asymmetric 
unit. 
 
Figure I.12: Overall structure of YePykF. (a) Topology diagram representing the overall folding of YePykF. 
Secondary structure elements are colored according to domains: A domain - cyan, B domain – green, C domain 
- pink. (b) A cartoon representation of the YePykF+FBP tertiary structure. The catalytic site (violet), and 
allosteric site (yellow orange) are indicated. (c) Quaternary structure of YePykF+FBP. 
The physiological tetramer forms through interactions of the small interface (between Chain 
A and Chain D, or between B and Chain C). The water accessible surface of the tetramer is 
about 72180 Å
2
 and about 10300 Å
2
 of the surface area is buried in YePykF, whereas about 
69430 Å
2
 is water accessible and about 11450 Å
2
 is buried in the YePykF+FBP tetramer. 
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Two α-helices (α10, Lys351-Lys372; α13, Ala424-Ser440) and a C terminal loop-β-strand 
motif (Gly454-Leu470) and the same elements from adjacent molecules are involved in the 
formation of the small interface (Figure I.14 b).  
 
Figure I.13: Interfaces of YePykF. Chain A of YePykF and YePykF+FBP are superposed and shown in 
surface and colored light green. Secondary elements that involved in the interface interaction are shown as 
cartoon (a) Large interface of adjacent A domains (PykF+FBP: yellow, PykF: gray); (b) Small interface of 
adjacent C domains, (PykF+FBP: light blue, PykF: gray). The α-helices and β-strands are numbered according 
to the protein secondary structure; the N-terminal and the C-terminal of each helix are marked out as blue letters. 
In the YePykF structure, 15 hydrogen bonds and one salt bridge are formed by 19 residues 
from each subunit’s C domain and the interface area is 875 Å2 for monomers A and D on 
average. In YePykF+F16BP, only 8 hydrogen bonds are formed by 14 amino acids, and the 
interface area 656 Å
2
 (Table I.2). The solvation free energy gain of YePykF for interface 
formation (ΔiG = -6.9 kcal/mol) is lower than that of YePykF+FBP (ΔiG = -7.4 kcal/mol). 
The lower solvation free energy gain of YePykF might be the reason for PDBePISA as 
artifacts of crystal packing. However, the solvation free energy gain upon formation of the 
tetramer assembly for YePykF (ΔintG = -190.9 kcal/mol ) and YePykF+FBP (ΔintG = -68.4 
kcal/mol) suggests the tetramer is stable in solution. Compare to YePykF, the number of 
interaction residues and the area of the small interface are decreased in YePykF+F16BP. One 
explanation for this could be the conformational change of the effector-binding site. FBP and 
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sulfate groups binding sites involve three loops, one of which (loop N, the loop before the N-
terminal β21) is involved in interface formation. F16BP binding changes the conformation of 
loop N and results in less interactions, although there is no hydrogen bond or salt bridge 
involved in this loop.  
Table I.2: Interface properties of YePykF and YePykF+F16BP 
Interface Structure 
Chain 
ID 
Interface
 residues 
Interface  
 area (Å2) 
Hydrogen 
bonds 
Salt 
bridges 
CSS* 
Large 
interface 
YePykF 
A 
30 1112 16 1 0.20 
B 
YePyk+FBP 
A 
39 1456 17 8 0.46 
B 
Small 
interface 
YePykF 
A 
29 875 8 4 0 
D 
YePyk+FBP 
A 
24 656 8 0 0.19 
D 
*: CSS, Complex Formation Significance Score, ranges from 0 to 1 as interface relevance to complex formation 
increases. 
I.3.5  Allosteric site of YePykF 
To obtain structural information concerning the allosteric mechanism of YePykF, F16BP was 
added to YePykF protein in co-crystallization experiments. Three dimensional crystals 
(Figure I.11) of YePykF+FBP were obtained. X-ray diffraction datasets were collected with 
synchrotron radiation with the highest resolution limit of 1.9 Å. Molecular replacement was 
performed against a trimmed model from E.coli Pyruvate kinase PykF (PDB code: 1E0T). 
After manual building in Coot and refinement with Phenix.refine, F16BP electron density is 
clearly visible in a cleft in the C domain. The F16BP electron density was well defined to the 
σ level of 3.0 in Fo - Fc omit map and has peak heights greater than 1σ in an unbiased 2Fo - 
Fc map (Figure I.14 a). F16BP forms salt bridges and hydrogen bonds with neighborhood 
residues.  The 1’- phospho group of F16BP forms direct hydrogen bonds to side chains and 
backbones with Thr378, Gly379, Lys382 and Ser383. The 6’- phospho group forms direct 
hydrogen bonds with Arg353 and Thr355. The C2 hydroxyl group of D-fructofuranose forms 
hydrogen bonds with Thr355 and Thr462. Additionally, some indirect interactions are 
mediated by water molecule networks involving residues Ala455, Gly380, Gly381 and 
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Thr461.  The distance between the two phosphorous atoms in the YePykF +FBP structure is 
8.3 Å. 
In the YePykF structure, each monomer in the asymmetric unit binds two sulfate groups 
(SULF1 and SULF2). This is because YePykF was crystallized in conditions containing a 
high concentration of ammonium sulfate. As reported previously, the allosteric effector-
binding site of YePykF is capable of binding sulfate ions (Morgan et al., 2010). SULF1 
occupies a position corresponding to 1- phosphate of F16BP in the YePykF+FBP structure. 
SULF1 forms hydrogen bonds with hydroxyl groups from Thr378 and Ser383, and extra 
hydrogen bonds with the nitrogen atoms from Lys382, Gly379, and Ser383. SULF1 also 
forms hydrophobic interactions with Gly380, Ser459 and Gly460. SULF2 forms bonds that 
interlink the A and C domains. SULF2 is hydrogen-bonded to the Arg271 from the A domain, 
and to the Arg353 and Lys382 from the C domain. It also forms hydrophobic interaction with 
Thr355 from the C domain. The distance between the two sulfur atoms in YePykF structure 
is 9.2 Å. The interacting residues and distances are shown in Figure I.14 b. 
The detailed interactions in the effector-binding site were further analyzed by ligplot. 
Compared to the sulfate groups in the YePykF structure, F16BP molecules in the 
YePykF+F16BP structure bind to more amino acids through hydrogen bonds and 
hydrophobic interactions. 13 hydrogen bonds with 7 residues for F16BP in YePykF+F16BP 
compare to 10 hydrogen bonds with 6 residues for sulfate groups in YePykF. Hydrophobic 
interactions with 4 residues of F16BP in YePykF+F16BP compare to 3 residues of sulfate 
groups in YePykF. Moreover, the distance between the 2 phosphorous atoms of F16BP is 8.3 
Å compare to 9.2 Å of the two sulfur atoms (Figure I.15).  
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Figure I.14: YePykF Effector binding site. Selected residues are shown as sticks, F16BP and sulfate groups 
are shown as sticks and spheres. (a) A stereo view of F16BP binding site. F16BP was omitted for calculation of 
the Fo-Fc omit map (green mesh, 3σ). The 2Fo-Fc map was calculated using the whole YePykF+F16BP refined 
model (blue mesh, 1σ). (b) A stereo view of sulfate groups binding sites. SULF1 and SULF2 were omitted for 
calculation of the omit map (green mesh, 3σ). The 2Fo-Fc map was calculated using the whole YePykF refined 
model (blue mesh, 1σ). (c) Superposition of two effector bindings sites. YePykF is colored grey and 
YePykF+FBP is colored yellow. Sulfate groups are colored blue and F16BP is colored green and orange. 
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Figure I.15: Schematic representation of interactions in effector site. Black balls represent carbon atoms, 
red balls represent oxygen atoms, blue balls represent nitrogen atoms, and yellow balls represent phosphorous 
atoms. Hydrogen bonds and important interactions indicated by dashed lines are colored green and black 
respectively. Distances are indicated in Angstroms. Hydrophobic contacts are represented by arcs in which 
spokes radiating towards the contacting ligand atoms are colored brown. (a) Interactions between F16BP and 
YePykF effector site. (b) Interactions between sulfate groups and the YePykF effector site. 
Comparing the two YePykF structures, we could conclude the effector-binding site has a high 
affinity for negatively charged sulfate and phosphate groups. The effect of F16BP activation 
is not dependent on phosphate, but on the D-fructofuranose. Superposition of the two 
effector-binding sites shows a different conformation of a loop region (Gly454 - Asn463). In 
the YePykF structure, this loop spans two sulfate groups. However, in YePykF+FBP, the D-
fructofuranose of F16BP occupies the position of the loop and pushes the loop away (Figure 
I.14 c). In previously reported structures, only phosphate or sulfate binding in the effector site 
does not activate PK (Bakszt et al., 2010; Rigden et al., 1999; Zoraghi et al., 2011b), but 
F16BP and F26BP do. The assumption is that D-fructofuranose of FBP causes a different 
conformation of the loop region and is responsible for the PK activation. 
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I.3.6 Structure determination of YePykA+AMP  
The type II pyruvate kinase of Yersinia Enterocolitica (YePykA) consists of 480 amino acids. 
Non-tagged YePykA was recombinantly expressed and purified. In the most complete crystal 
structure model, more than 96.7% of the amino acids could be interpreted in the electron 
density of the YePykA+AMP structure. However, the completeness of peptide chains varied 
among monomers in one asymmetric unit. 471, 462, 461 and 463 out of 480 amino acids 
could be interpreted for chain A, B, C and D, respectively. The first N-terminal methionine is 
not visible possibly because of its high flexibility or posttranslational modification.  
The secondary structure of YePykA was also determined from the DSSP algorithm and is 
shown in Figure S1. YePykA consists of similar secondary structure elements in specific 
positions to that of YePykF. Although the sequence identity between YePykF and YePykA is 
only 36.7%, YePykA subunits still share similar architecture with YePykF (Figure I.16 a). 
The tertiary structure of YePykA can also be divided into 3 distinct domains: the rigid A 
domain (residues 1 to 74 and 172 to 348, cyan), composed of an (α/β)8 barrel and small α-
helices; the flexible B domain (residues 75 to 171, green), composed of 7 β-strands, one 
small α-helix and almost 50% random coils; the C domain (residues 349 to 480, light pink), 
composed of helices and strands forming an αβαβαβαββ topology. The mainly difference 
between YePykA and YePykF is located in B domain. Seven β-strands and one small helix 
were found in YePykA’s B domain, whereas 11 β-strands and no helix were found in 
YePykF’s B domain.  
The four monomers in the asymmetric unit are arranged as a tetramer similar to type I PKs. 
Every two monomers interact with each other through hydrogen bonds and salt bridges. The 
webserver PDBePISA was again used for analyzing the assembly of the asymmetric unit. The 
water accessible surface of YePykA tetramer is 80969 Å
2 
and about 4484 Å
2
 of surface area 
is buried. The analysis revealed the largest interfaces could be found between the monomers 
A and B as well as C and D (1132 Å
2 
on average). The smaller interfaces could be located 
between monomers A and D as well as B and C (1042 Å
2
 on average). The detailed 
information about the number of residues and bonds, which are involved in the interface 
formation, are listed in Table II.3. The solvation free energy for the large interfaces (ΔiG = -
17.9 kJ/mol on average) is higher than that of the small interfaces (ΔiG = -11.4 kJ/mol on 
average). PDBePISA judges all the interfaces as 100% relevant for complex formation and 
suggests the tetramer as the physiological relevant oligomer. 
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Figure I.16: Structure of YePykA. (a) A cartoon representation of the YePykA monomer. Structural domains 
are colored differently; A domain – colored cyan, B domain – green, C domain – light pink. The Aα6’ helix is 
colored in red. (b) A cartoon representation of the YePykA tetramer. Chain A is colored according to domains; 
chain B, chain C and chain D are colored as yellow, light blue and orange, respectively. 
Table I.3: Interface properties of YePykA tetramer 
Interfaces Chain ID 
Interface 
residues 
Interface  
area (Å
2
) 
Salt 
bridges 
Hydrogen 
bonds 
CSS* 
Large 
interface 
A 
32 1147 3 7 1 
B 
C 
43 1256 6 9 1 
D 
Small 
interface 
A 
28 1030 3 11 1 
D 
B 
27 1053 0 11 1 
C 
*CSC: Complex Formation Significance Score, CSC ranges from 0 to 1 as interface relevance to complex 
formation increases. 
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I.4 Discussion and outlook 
I.4.1 YePykF allosteric mechanism 
As was reported before, PKs exist in either the T-state (inactive) or the R-state (active) 
enzymes. The T-state and R-state enzymes can switch between each other depending if the 
allosteric effector is present. One exception is the mammalian muscle isoenzymes, which 
always exists as the R-state and constitutively active in absent of allosteric effectors (Rigden 
et al., 1999). In the last 20 years, many efforts have been made to explore the mechanism of 
allosteric regulation. Researchers have tried to compare different states of enzymes from 
different organisms, and speculated that the allosteric regulation mechanism might be the 
effector induced B domain closure (Christofk et al., 2008; Dombrauckas et al., 2005; Rigden 
et al., 1999; Tulloch et al., 2008).  For example, Mattevi et al. (1995) compared the T-state E. 
coli PK with the non-allosteric rabbit muscle enzyme PKM1, which is thought to adopt a 
conformation similar to the active R-state, and revealed the allosteric strategy is the rotations 
of B and C domains by 17° and 15°, respectively. The comparison between the F16BP-
binding human PKM2 (hPKM2) with the T- and R-states of rabbit muscle PKM1, revealed 
the partial B domain closure after F16BP binding (Dombrauckas et al., 2005). However, 
these evidences are not based on PK structures from the same organism, and B domain is 
even reported to adopt different conformations among different subunits in the same PK 
tetramer (Bakszt et al., 2010). To prove the effector induced B domain closure allosteric 
strategy, direct evidence about the effector-free and effector-bound PK structures from the 
same organism are needed. Pyruvate kinase from Leishmania mexicana has been studied to a 
large content. The transition of Leishmania mexicana pyruvate kinase from T-state to R-state 
can be summarized as a simple symmetrical 6° rigid body rocking motion of the AC cores (A 
domain and C domain) in each of the four subunits, and the formation of eight salt bridges 
across the small interface, but the B domain movement is not reported as allosterically 
regulated (Morgan et al., 2010). Commonly, there is a significant structural divergence 
between prokaryotes and eukaryotes, which has hampered a detailed understanding of the 
allosteric regulation mechanism of prokaryotic PKs.  
In this work, Yesinia PK structures of both T- and R- states from the same species have been 
solved. The comparison between them revealed a detailed allosteric regulation mechanism of 
prokaryotic PKs. To quantify the structural differences upon F16BP binding, I superposed the 
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Cα atoms of the AC domains from YePykF and YePykF+FBP onto each other, and 
calculated the Cα r.m.s. deviations of each residue. Superposition of YePykF_chain_A and 
YePykF+FBP_chain_A shows slight difference in chain A but tremendously conformational 
change in the B domain of chain B. (Figure I.17 a). The B domain has a maximum Cα r.m.s. 
deviations of 15 Å and 9.6 Å on average. Superposition of asymmetric dimer of two 
structures shows similarly conformational changes in both subunits (Figure I.17 b). The 
average Cα r.m.s. deviations for B domains of two subunits are 5.6 Å and 4.1 Å, compared to  
the AC domains  whose Cα r.m.s. deviations are 0.9 Å and 0.92 Å,  respectively. Despite B 
domain, a loop region (residue 452 to residue 463) also shows large Cα r.m.s. deviations with 
an average value of 5.3 Å. Checking with the structure, this loop region is exactly involved in 
F16BP binding. The conformational change of the loop region was already discussed in I.3.5 
From the superposition results we could derive that YePykF has an open conformation of B 
domain and belongs to the T-state, whereas YePykF+F16BP has a closed conformation of B 
domain and belongs to the R-state. The closing of the B domain narrows the cleft between A 
and B domains. In order to quantify the B domain movement, the distance between domain B 
and domain A were measured. Distances of the Cα carbons of residues Asp127 (from domain 
B) and Val249 (from domain A) were measured to indicate the biggest distance between the 
domain A and domain B. The distance was 10.9 Å in YePykF, and this value decreased to 6.7 
Å in YePykF+FBP (Figure I.17 a). The molecular parameters LWH (length, width, height) 
were also measured to quantify this B domain movement effect.  The orthogonal parameters 
of YePykF are 137 × 86 × 96 Å
3
, and these were decreased to 132 × 84 × 86 Å
3
 in 
YePykF+F16BP structure (Figure I.18), which can be interpreted as B domain movement 
yields a smaller spatial volume and tighter stacking of monomers. 
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Figure I.17: Superposition of YePykF+F16BP and YePykF. (a) Superposition of the Cα atoms of 
YePykF+F16BP_chain_A and YePykF_chain_A. (b) Superposition of the Cα atoms of YePykF+FBP and 
YePykF asymmetric dimer. The diagram shows the Cα r.m.s. deviations of every residue, and the black dashed 
line boxes indicate B domains. The pictures below show the corresponding superposition of two structures in 
Pymol, YePykF is colored in gray, YePykF+F16BP is colored in violet, and the distances between Asp127 and 
Val249 are indicated in green dashed lines. 
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Figure I.18: Orthogonal view of homotetrameric YePykF and YePykF+F16BP. (a) The orthogonal 
parameters of YePykF are 137 × 86 × 96 Å
3
. (b) The orthogonal parameters of YePykF+F16BP are 132 × 84 × 
86 Å3.  
To further describe the domain motions, the program DynDom (Hayward and Berendsen, 
1998; Hayward and Lee, 2002; Poornam et al., 2009) was employed. The DynDom program 
measures the rotation degree and translation of one domain of the protein against the protein 
rigid body. The moving domains and bending residues calculated by DynDom are exactly the 
B domains and their domain borders. Based on DynDom analysis, the conformational change 
of YePykF upon F16BP binding can be concluded as follows: B domain pivots around 
residues 68-71 and residues 165-171 and rotates towards A domain by 9.6° and 19.6° for 
chain A and chain B respectively (Table I.4). The average value of the B domain rotation is 
14.6°. The rotation of B domain changes the volume of the active cleft, and yields a partial 
closure active site. 
Table I.4. DynDom analysis of two chains of YePykF and YePykF+F16BP 
Confomer 1 Confomer 2 
Moving 
domain 
Bending 
residues 
Rotation 
angle (°) 
Closure 
(%) 
Cα RMSD of AC 
domain (Å) 
PykF chain A 
PykF+FBP 
chain A 
- - - - - 
PykF chain B 
PykF+FBP 
chain B 
69-170 
68-69 
165-171 
28.8 95.7 1.42 
PykF chain A 
PykF+FBP 
chain B 
65-186 
64 -66 
186-187 
9.6 95.6 1.36 
PykF chain B 
PykF+FBP 
Chain A 
70-168 
69 -71 
167-169 
19.5 88 1.47 
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I.4.2 Catalytic site of YePykF  
As is shown before, the catalytic site of YePykF and YePykA should be located in a pocket 
between A and B domains of each subunit, assuming conservation of the catalytic region of 
PKs. A two turn Aα6’ helix (243 RGDLGVE249), which is considered necessary for enzyme 
activity, is highly conserved (Cook et al., 2012). According to Morgan et al. 2010, residues 
(Arg32, Asn34, His37, Arg73, Lys220, Glu222, Gly245, Asp246, Thr278 and Ser312) 
involved in substrate binding are well conserved in yeast, rabbit, human, and E. coli 
sequences (Figure I.19 a). This conservation is also present in Yesinia pyruvate kinases 
sequence for YePykF and YePykA, and the conserved residues could be located in the 
concave between A and B domains. Despite Aα6′ helix, all catalytic residues were located on 
or next to the β-strands core of the (α/β)8 barrel. β-strands Aβ2 and Aβ5 Aβ are directly 
involved, whereas Aβ3, Aβ5 and Aβ7 associated loops are involved in the enzyme catalytic 
activity (Figure I.19 b).  
 
Figure I.19: Catalytic site of YePykF. (a) Structure based sequence alignment of active site associated 
sequence of pyruvate kinase from different species. Identical residues are highlighted in red and similar residues 
are surrounded by a blue box. The conserved residues involved in the active site are marked out with black stars. 
(b) Cartoon view of catalytic residues in YePykF structure. Aα6′ helix is colored in red, and catalytic residues 
are shown as sticks and colored in blue. 
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In the case of YePykF chain B for example, B domain pivots around residues 68 - 69 and 
residues 165 - 171 and rotates towards A domain by 28.8°. This B domain movement 
decreased of the biggest distance between domain A (Val249) and domain B (Asp127) from 
10.9 Å to 6.7 Å and thus makes the concave between A and B domains smaller. The smaller 
spatial volume of active site could facilitate the substrate binding and stabilize it. Once the 
catalytic reaction was performed, the product was released and gives space for new substrate. 
Apart from the B domain movement, the Aα6’ helix is found unwound in YePykF but helical 
in YePykF+FBP structure (Figure I.20). The unwinding of Aα6’ helix has also been reported 
in the inactive state of Cryptosporidium parvum and Leishmania Mexicana PKs (Cook et al., 
2012; Morgan et al., 2010). As was discussed, the Aα6’ helix is necessary for the enzyme 
activity. This has led to proposition of a model for the structural rearrangement at the active 
site (Cook et al., 2012; Morgan et al., 2010; Tulloch et al., 2008) from R- to T-state.  
 
Figure I.20: Comparison of YePykF (T-state) and YePykF+FBP (R-state). Superposition was done with 
YePykF_chain_B and YePykF+FBP_chain_B. YePykF is colored light yellow, the unwound Aα6’ helix is 
colored red. The B domain (residues 71–167) is shown in cyan for the YePykF +FBP structure, and the AC 
domain is violet.  The Cα atoms r.m.s. derivations value of domains A and C (residues 1 – 70 and 168 – 470) is 
1.42 Å. The 28.8° movement of domain B corresponding to the closure of the active site is highlighted. 
The electrostatic surface potential of YePykF was also analyzed to characterize the active site. 
The electrostatic surface potential was calculated by APBS (Baker et al., 2001), which shows 
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the active pocket to be highly negatively charged (Figure I.23 a).  Since ADP and PEP are 
negatively charged, the substrates binding must have the aid of metal ions such as K
+
 and 
Mg
2+
. According to Morgan et al., substrates ADP, PEP and metal ions (K
+
, Mg
2+
) bind to 
the active site through hydrogen bonds, ionic bonds and mediating water molecules.  
The MolProbity (Davis et al., 2007) geometry analysis of YePykF+FBP model shows that 
two residues (Thr278 and Ser312) that are crucial for PK catalysis exhibit geometry out side 
of the favored regions of the Ramachandran plot, although they correlate well with the 
electron density map (Figure I.21). This phenomenon has also been observed in many other 
PK structures. The abnormal geometry of residues Thr278 and Ser312 is due to restricted 
geometry, which facilitates the interactions with the substrates (Mattevi et al., 1995; Morgan 
et al., 2010). However, the abnormal geometry didn’t show in YePykF structure. It is 
speculated that the abnormal geometry of Thr278 and Ser312 is due to the presence of F16BP, 
although it’s not clear how F16BP affects these two amino acids. It is also possible that the 
absence of the two residues’ abnormal geometry in YePykF is due to the low quality of the 
X-ray diffraction data.    
 
Figure I.21: Geometry of active site of the YePykF+FBP model. (a) Electron density map of Thr278 and 
Ser312, contoured at 1.5 σ. (b) Ramachandran plot of refined structure model of YePykF+FBP. 
I.4.3 Effector binding sites of YePykF and YePykA 
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In the presence of allosteric effectors, the catalytic ability of PKs is clearly higher than 
without allosteric effectors (Morgan et al., 2013; Zhong et al., 2013). The residues involved 
in F16BP binding of YePykF are well conserved in type I Enterobacteriaceae PKs, but show 
less conservation compared to type II PKs and type I PKs in other species (Figure I.22). The 
electrostatic surface potential shows that the effector-binding position is highly positively 
charged, which facilitates the binding capacity of negatively charged F16BP molecules 
(Figure I.23 b). The first binding effect is the conformational change of the binding site. 
Comparing the effector-binding site of the YePykF+FBP and YePykF structures reveals that 
the loop N (Gly454 - Asn463) which spans between two sulfate ions in YePykF, changes its 
conformation upon F16BP binding. The effector-binding site is capable of binding sulfate 
and phosphate but these ions could not activate PK. We speculate that the activation strategy 
of F16BP is not depending on phosphate groups, but on the presence of the D-fructofuranose 
moiety of F16BP. The phosphate groups of F16BP merely facilitate the binding but not 
involved in the activation of YePykF. From the superposition, we found that the D-
fructofuranose in YePykF+FBP structure occupies the position of the loop N and pushes the 
loop out. The primary conformational change of the loop N might cause a hinge motion and 
lead to the secondary conformation change of the B domain, which is 40 Å away from this 
effector-binding site, and thus trigger the activation of the enzyme.  
 
Figure I.22: Structure based sequence alignment of the effector binding site associated sequence of 
pyruvate kinase from different species. Identical residues are highlighted in red and similar residues 
surrounded by a blue box. For YePykF, the residues involved in F16BP binding are indicated by asterisks. 
Chapter I: Structural analysis of Yersinia pyruvate kinases reveals the allosteric strategy  
44 
 
Figure I.23: Electrostatics of YePykF+FBP showing the empty active site and F16BP binding site. Blue: 
positive; red: negative. 
Due to the low resolution X-ray diffraction data of PykA+AMP crystals, no electron density 
for AMP molecules could be seen in the electron density map. So far, only one type II 
pyruvate kinase structure from Geobacillus stearothermophilus (GstPK, PDB code: 2E28) 
has been solved at a resolution of 2.4 Å (Suzuki et al., 2008). GstPK has an extra C-terminal 
sequence (ETCS) composed of 110 residues. The ETCS forms a C’ domain, which is next to 
the C domain. A sulfate ion was found in the C domain. The sulfate-binding site resembles 
the 6-phosphte group of F16BP-binding site in yeast PK, and is proposed to be the effector-
binding site. According to Suzuki et al., the sulfate-binding involves two threonine residues 
(Thr381 and Thr386) and a histidine residue (His425) (Figure I.24). The sequence identity 
between YePykA and GstPK is only 31.2%, but the sequence alignment shows that the three 
residues (Thr386, Thr391, his431) in YePykA are conserved with those in GstPK. These 
three residues associated loops and helix might be the AMP binding site. However, since 
little information is known about type II PKs, they could also have a quite different effector-
binding site from the type I PKs. In our YePykA structure model, strong unexplained electron 
density was observed at His375 imidazole group. The His375 might also be the potential 
AMP binding site. But the probability is very low, because the imidazole group of His375 
points out of the monomer and capable of binding metal ions. The strong electron density 
might due to the binding of unknown metal ions. 
  Chapter I: Structural analysis of Yersinia pyruvate kinases reveals the allosteric strategy 
45 
 
Figure I.24 Superpostion of YePykA and GstPKNC reveals potential effector binding site. YePykA and 
GstPKNC are shown in cartoon. YePykA is colored in light blue; the predicted active site Aα6′ helix is colored 
in red; the potential effector binding residues are shown in sticks and colored in blue. GstPKNC is colored in 
light yellow; the sulfate group is shown in sticks and sphere; the sulfate binding residues are colored in orange. 
I.4.4 Allosteric mechanism of YePykF  
That substrate-binding causes B domain closure of PKs has been reported for Leishmania 
mexicana (Morgan et al., 2010) and Trypanosoma brucei (Zhong et al., 2013). The X-ray 
structure determination of YePykF and YePykF+F16BP revealed the B domain closes 
partially after the effector molecules bind to the allosteric site. In summary, the allosteric 
mechanism of prokaryotic PKs could be proposed as the effector-induced B domain 
movement, which leads to a partial closure of the active site, and changes the conformation of 
PK enzyme from T- to R-state (Figure I.25 b). The active site closure is not only depending 
on the substrate binding, but also on the effector binding to the allosteric site (Figure I.25 d). 
Allosteric sites usually show less conservation among species than highly conserved active 
sites. Based on this, the structural information of diverse PK isoforms, especially the 
allosteric sites, could eventually be utilized for drug design. 
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Figure I.25: YePykF crystal structures revealed the allosteric mechanism. (a) Schematic representation of 
the inactive T state YePykF structure (apoenzyme); (b) Binding of F16BP causes a partial closure of B domain 
and a broader C-C distance, YePykF changes from T state to R state; (c) Binding of substrates to the 
YePykF+FBP, theoretically causing a completely closure of B domain; (d) Binding of substrates to the 
apoenzyme causes a B domain movement and changes the enzyme into R state. (b, c, d) YePykF are colored in 
different domains, A domain, cyan, B domain, green, C domain, pink.  
I.4.5 Catalytic function of YePykF and YePykA 
Based on the sequence alignment result of PKs, YePykA conserves the catalytic site similar 
to YePykF. The Aα6′ is still present in the YePykA+AMP’s structure and clearly defined as a 
two turn helix. The catalytic site of YePykA can be similarly located in the pocket between 
the B and A domains as in YePykF. As was mentioned before, PykA has lower catalytic 
ability in all tested conditions (Hofmann et al., 2013; Ponce, 1999; Siddiquee et al., 2004). 
The reason why Enterobacteria need two types of pyruvate kinases is still not clear. By 
superimposing YePykF+FBP and YePykA+AMP, two structures showed high similarity 
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(Figure I.26). Two loop regions (residues 83-85 and 150-152, colored pink) in 
YePykA+AMP structure are defined as β-strands in YePykF+FBP structure. This might due 
to the low data quality of YePykA+AMP structure.  But one well-defined β-strand (residues 
162-164, colored yellow) in YePykA+AMP structure is present as a loop in YePykF+FBP 
structure. This β-strand is located between B and A domains. We speculate the extra β-strand 
in YePykA+AMP might restrain the flexibility of B domain and also affect the spatial 
volume of the active site upon substrates binding. Hence the small β-strand might contribute 
to the lower catalytic ability of YePykA. To prove this, the future research should focus on 
getting better quality of YePykA and YePykA plus substrates structures. 
 
Figure I.26: Superposition of YePykA+AMP and YePykF+FBP structures. Structures are shown in cartoon. 
YePykA+AMP is colored light blue, the β-strand (residues 162-164) is colored yellow. YePykF+FBP is colored 
in light green; two β-strands (residues 83-85 and 150-152) are colored pink. 
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II.1  Introduction 
II.1.1 Viral infection  
A virus particle (also called virion) is a microscopic infectious entity consisting of only one 
type of genetic material, either DNA or RNA, surrounded by a protein, lipid or glycoprotein 
coat. A virus is not capable of replicating itself but requires the use of the machinery and 
metabolism system of the cells (Figure II.1). Viruses can infect all living forms, including 
animals, plants, bacteria and archaea (Koonin et al., 2006). Viral infections are more systemic 
than localized bacterial infection. Antibiotics usually target the bacteria replication machinery 
and enzymes, systems that viruses do not possess. Hence viral infections cannot be treated by 
antibiotics. 
 
Figure II.1: A schematic diagram of the virus replication cycle (for example, HCV follows the same 
infectious path). (a) Attachment and endocytosis; (b) uncoating; (c) IRES-mediated translation and polyprotein 
processing; (d) RNA replication; (e) virion packing; (f) virion maturation and release. Adapted from Moradpour 
et al. (2007). 
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II.1.2 Hepatitis C virus infection 
Hepatitis C virus (HCV) is the major causative pathogen of acute and chronic liver diseases, 
liver cirrhosis, hepatocellular carcinoma and liver failure. Approximately 160 million people 
are infected worldwide, with an estimated 130 million with a chronic infection (Lavanchy, 
2009). Among all the cases, ~27% liver cirrhosis and ~25% of hepatocellular carcinomas are 
correlated with HCV infection, which makes chronic hepatitis C infection a major indicator 
for liver transplantation. No vaccine is available and current therapies are effective against 
some genotypes but not all (Simmonds, 2013). 
HCV is a member of the genus Hepacivirus within the family Flaviviridae. It has a positive-
strand RNA genome and lipid associated envelope. Due to the high genomic variability, HCV 
has seven genotypes (numbered 1-7), most of which have subtypes, named a, b, and so on. 
The 9.6 kb RNA genome contains one long open reading frame (ORF) flanked by highly 
structured 5’ and 3’ non-translated regions (NTRs) (Figure II.2 a). The ORF encodes a 
polyprotein containing ~ 3000 amino acids. The polyprotein is processed into 10 different 
structural and non-structural proteins by protease. The structural proteins and P7 are 
generated by host signal peptidase or signal peptidase mediated cleavages. NS2 and non-
structural proteins are processed by the viral cysteine protease NS2-3 and serine-type 
proteaseNS3-NS4A complex. Structural proteins (core protein, E1, E2), P7 and NS2 are 
classified as the assembly module. P7 and NS2 play the supporting role for viral particle 
assembly but are not incorporated into the virus particle.  The non-structural proteins NS3, 
NS4A, NS4B, NS5A and NS5B, which are function for virus RNA replication, are classified 
as replication module (Figure II.2 a). Every protein is partially embedded into intracellular 
membranes by one or several transmembrane elements. E1 and E2 form heterodimer, NS5A 
form homodimer, and P7 forms oligomeric complexes (Figure II.2 b). 
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Figure II.2: Hepatitis C virus genome organization and the membrane topology of cleaved viral proteins. 
(a) The hepatitis C virus (HCV) ORF encoding a polyprotein, and the predicted secondary structures of 5′ and 3′ 
NTRs. Start and stop codons of the ORF are indicated by black dots. The internal ribosome entry site (IRES) is 
contained within 5′ NTR. (b) Membrane topology and major functions of the HCV polyprotein cleavage 
products (Bartenschlager et al., 2013). 
The HCV particle (virion) is enveloped by a membrane, with glycoproteins E1 and E2 
displayed on the surface. It has been reported to be 40 - 80 nm in diameter, pleomorphic, 
lacking obvious symmetry or surface features and containing an electron dense core (Figure 
II.3 a) (Bradley et al., 1985; Catanese et al., 2013b; Gastaminza et al., 2010; He et al., 1987; 
Merz et al., 2011). HCV particles have been observed to have low buoyant density, much 
lower than expected for a protein-envelope virion particle. The lower buoyance is due to their 
association with serum lipoproteins, including apolipoprotein A-I (apoA-I), apoB-48, apoB-
100, apoC-I and apoE (Catanese et al., 2013b; Diaz et al., 2006; Felmlee et al., 2010; Kono et 
al., 2003; Lindenbach, 2013; Merz et al., 2011; Thomssen et al., 1992). This association 
between virus particles and serum lipoproteins indicates that HCV particles exist as hybrid 
‘lipoviral particles’ (LVPs). The benefit of this association can prevent the virus from 
antibody neutralization due to the shielding of the envelope protein epitope. Liver cells take 
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up lipoprotein via receptor-mediated endocytosis, which facilitate virus entry into 
hepatocytes (Ross-Thriepland et al., 2013). However, the overall architecture of LVPs 
remains unclear. Currently, there are two models proposed for the structure of LVPs: the 
transiently interacting model and the hybrid particle model (Figure II.3 b, c). 
 
Figure II.3: Models of hepatitis C virus (HCV) lipoviral particle (LVP) structure. (a) Model of a hepatitis 
C virus (HCV) particle, showing the bilayer membrane envelope, E1–E2 surface glycoproteins, and the 
nucleocapsid containing core protein and viral RNA. (b) The transiently interacting model for lipoviral particle 
(LVP) structure. (c) The hybrid particle model for LVP structure, illustrating an HCV particle sharing an 
envelope with a low-density lipoprotein (LDL) particle, adapted from Lindenbach and Rice, et al. (2013). 
HCV entry is the first step of the HCV infection process. It requires the cooperation of 
numerous factors in a temporally and spatially ordered manner (Figure II.4). A series of host 
membrane proteins are involved in this entry process; these are HSPG (heparan sulphate 
proteoglycans), LDLR (low-density-lipoprotein receptor), SRB1 (scavenger receptor class B 
type I), CD81, EGFR (epidermal growth factor receptor), CLDN1, OCLN and so on. 
Lipoprotein-associated HCV particles attach to the surface of hepatocytes via low affinity 
interaction between virion-associated apoE and its host acceptors, LDLR and 
glycosaminoglycans (GAGs) that are presented on HSPGs (Agnello et al., 1999; Albecka et 
al., 2012; Germi et al., 2002; Monazahian et al., 1999). The high density lipoprotein receptor 
SRB1 also serves as a HCV receptor; its cholesterol transfer activity might help virus particle 
dissociate from their LVPs, and its interaction with HCV E2 glycoprotein might change the 
conformation of E2 for exposing the CD81-binding determinants (Bankwitz et al., 2010; Dao 
Thi et al., 2012; Scarselli et al., 2002; Zahid et al., 2013).  The critical step in HCV entry is 
the lateral movement of CD81-bound HCV particles to tight junctions and the CD81-HCV 
complex interacts with claudin-1 (CLDN1). Several signal transduction pathways involving 
EGFR and downstream RAS GTPase signaling, as well as RHO GTPases regulate this cell 
surface transportation (Brazzoli et al., 2008; Diao et al., 2012; Farquhar et al., 2012; 
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Lupberger et al., 2011; Zona et al., 2013). The interaction of HCV-CD81 with CLDN1 
triggers the clathrin-mediated endocytosis and translocates HCV particles into hepatocytes 
(Farquhar et al., 2012). Although occludin (OCLN) is also reported to be essential for HCV 
entry, its specific role is not clear at the moment (Ploss et al., 2009; Sourisseau et al., 2013). 
 
Figure II.4: An integrated model of HCV entry. Step 1: low affinity interaction of LVPs with HSPGs and 
LDLR and SRB1. The interaction with SRB1 might change the conformation of HCV E2 glycoprotein, 
exposing the binding site to CD81; Step 2: the interaction of HCV E2 with CD81 activates signal transduction 
through EGFR, RAS GTPases and RHO GTPases; Step 3: Signal transduction promotes HCV-CD81 movement 
to the tight junction; Step 4: Clathrin mediated endocytosis; Step 5: Low pH induces HCV fusion in the 
endosomal compartment. NPC1L1, Niemann - Pick C1-like 1; OCLN, occludin (Lindenbach and Rice, 2013). 
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II.1.3 HCV envelope proteins 
HCV envelope glycoprotein 1 (E1) and envelope glycoprotein 2 (E2) are type I 
transmembrane proteins with a highly glycosylated ectodomain and a C-terminal 
hydrophobic anchor. HCV E1 and E2 glycoproteins form a noncovalent heterodimer through 
their C-terminal transmembrane domains, which is essential for interaction with receptors 
and neutralizing mAbs (Drummer and Poumbourios, 2004; Lavie et al., 2007). E2 is 
composed of an ectodomain (ETD, residues 384 - 661) and a C-terminal transmembrane 
domain (residues 715 - 746), between which the stem region (residues 662 - 714) is located. 
E2 has 9 to11 N-linked glycosylation sites and 18 conserved cysteine residues. Despite these 
conservations, HCV E2 contains 3 hypervariable regions: hypervariable region 1 (HVR1, 
residues 384 - 411), hypervariable region 2 (HVR2, residues 460 - 485) and the 
intergenotypic variable region (HVR3 or igVR, residues 570 - 580) (Figure II.5). The 
deletion of the hypervariable regions has been shown to have no effect on the overall folding 
of the protein and the binding with CD1 and mAbs (Kato et al., 1992; Krey et al., 2010; 
McCaffrey et al., 2007; McCaffrey et al., 2011; Weiner et al., 1991). 
 
Figure II.5: Schematic representation of HCV E2 glycoprotein domain organization. HVR1, HVR2 and 
HVR3 are indicated as red frames. The TM domain is colored in green; the stem region is colored in orange. 
The borders of each region are indicated as amino acids numbers. 
II.1.4 HCV human receptor SRB1 
Scavenger receptor class B type I (SRB1) is a 509 amino acids glycoprotein and belongs to 
the CD36 superfamily. It is composed of a larger extracellular domain, which is highly 
glycosylated and contains disulfide bonds, and two transmembrane domains at both N- and 
C- termini (Figure II.6) (Calvo and Vega, 1993; Krieger, 2001; Zeisel et al., 2007). SRB1 is 
primarily expressed in liver and non-placental steroidogenic tissues. Its normal function is to 
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bind high-density lipoproteins (HDLs), very-low-density lipoproteins (VLDLs) and oxidized 
forms of low-density lipoproteins (LDLs), and mediates the cholesterol uptake from these 
lipoproteins (Acton et al., 1996). SRB1 was also identified as a co-receptor of HCV particles 
based on the evidence of its interaction with recombinant HCV E2 on HepG2 cells in the 
absence of CD81, and promotes the cell-to-cell transmission of HCV virus (Bartosch et al., 
2003; Catanese et al., 2013a; Scarselli et al., 2002). The function of SRB1 during HCV entry 
has been divided into 3 steps. First, low affinity attachment of LVPs via lipoproteins occurs. 
Second, lipid transfer activity of SRB1 dissociates HCV particle and lipoproteins. Lastly, the 
direct interaction of SRB1 and E2 yields the determinants for CD81 binding (Lindenbach and 
Rice, 2013; Zahid et al., 2013). Previous reports show recombinant soluble E2 devoid of 
HVR1 exhibits decreased interaction with SRB1, and the entry of HCVpp lacking HVR1 no 
longer inhibited by SRB1-specific antiserum (Bankwitz et al., 2010; Scarselli et al., 2002). 
These results indicate the E2 potential interaction position for SRB1 might locate on the N-
terminal HVR1 region. 
 
 
Figure II.6: Schematic representation of the 
scavenger receptor class B type I protein. 
Structural elements include a large ectodomain, two 
transmembrane domains, and short intracellular N-
terminal and C-terminal domains. Glycosylation 
sites are colored in green, cysteine residues are 
colored in blue, and the transmembrane domains 
are colored in cyan. Numbers are according to the 
amino acids numbering of SRB1. The Figure was 
modified from Hoekstra et al. (Hoekstra et al., 
2010). 
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II.2 Aim of the work 
HCV E2 and SRB1 interaction is the first step in the protein-receptor interaction during HCV 
entry. The structures of SRB1 and HCV E2 were still unknown when this project was 
initiated. Furthermore, the interaction mechanism between SRB1 and E2 is still unsolved. 
The exploration of such knowledge will push forward our understanding of HCV entry 
process, and will assist in developing HCV vaccines and new entry inhibitors.  
II.3 Results  
II.3.1 HCV sE2 expression, purification and crystallization   
In the HCV envelope glycoprotein E2-ectodomain (sE2), N-linked glycans constitute nearly 
50% of the molecular weight. Folding of HCV E2 is a slow process and requires the 
assistance of ER chaperon machinery such as calnexin (Choukhi et al., 1998). Because of the 
high glycosylation and intermolecular disulfide bonds, a homogenous E2 protein cannot be 
obtained by normal expression strategies for crystallization. A high proportion of the 
expressed E2 forms aggregates through intermolecular disulfide bonds, which is common and 
has been proposed to be a physiologically relevant pathway of the HCV lifecycle (Dubuisson, 
2000; Michalak et al., 1997; Whidby et al., 2009). In order to get soluble, homogenous 
soluble E2 (sE2, residues 384-661) protein, three expression strategies (transient expression, 
baculovirus-insect cell expression and stable cell line) were performed simultaneously.  
HCV sE2 was fused with a His6 tag and cloned into a pcDNA 3.1-tpa eukaryotic expression 
vector and transfected into a HEK293 6E cell line with PEI (polyethylenimine). Together 
with transfection, 5μM kifunensine (α-mannosidases inhibitor) can be added to the culture to 
decrease the complexity of glycosylation. In the presence of kifunensine, protein 
glycosylation was decreased to the high mannose type. The high mannose type glycosylated 
protein can be truncated efficiently by endoglycosidases with only a single N-
acetylglucosamine (GlcNAc) left on each N-glycosylation site. Two glycosylation patterns 
(high mannose type and fully glycosylation pattern) of HCV sE2 have been expressed 
depending on the addition of kifunensine. HCV sE2 was purified from the supernatant of 
HEK 293 6E suspension culture with Ni-NTA affinity chromatography. The purification 
products were analyzed with SDS-PAGE. Due to glycosylation, the protein band appears 
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larger than its theoretical size. The theoretical size of sE2 is 31 kDa, but it appears to be 
around 55 kDa on SDS-PAGE (Figure II.7 a). The fully glycosylated sE2 appears smeary on 
SDS-PAGE, this is probably because of heterogeneous glycosylation. To verify sE2 
expression, a Western blot experiment using anti-His antibodies was performed. After 
staining, a band corresponding to that on SDS-APGE was visualized on the Western blot 
membrane (Figure II.7 b). High mannose type sE2 was also sent for N-terminal sequencing 
and this confirmed the first 13 amino acids of sE2. The high mannose sE2 protein has been 
deglycosylated with EndoHf and yielded two bands between 35 - 40 kDa on SDS-PAGE 
(Figure II.7 a). We speculate that these two bands are caused by heterogeneous glycosylation. 
The deglycosylated protein was then assessed by MALDI - TOF - mass spectrometry. The 
results revealed five partially used glycosylation sites among the 13 predicted ones. These 
partially occupied glycosylation sites are at Asn532 (90%), Asn576 (96%) and Asn623 (30%) 
and Asn (64%). The deglycosylated protein was further purified by cation exchange 
chromatography and then applied onto a size exclusion column. However, the protein shows 
considerate aggregation on size exclusion chromatography (Figure II.8 a).  To check if the 
aggregation is caused by deglycosylation, another size exclusion chromatography was 
performed with non-deglycosylated protein (high mannose sE2). Unfortunately, it shows 
similar behavior to the deglycosylated sample (Figure II.8 b). 
 
Figure II.7: Transiently expressed HCV sE2. (a) SDS-PAGE analysis of transiently expressed sE2 after 
affinity chromatography. 1: fully glycosylated sE2; 2: high mannose type sE2; 3: high mannose sE2 
deglycosylated with EndoHf. (b) Western Blot detection of HCV E2 using anti-His antibody. C: control sample 
of non-transfected HEK 293 6E cell supernatant; sE2: high mannose type of sE2. 
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Figure II.8: Size exclusion chromatography of sE2 shows considerate aggregation. (a) Size exclusion 
chromatography of deglycosylated sE2; (b) Size exclusion chromatography of non-deglycosylated sE2. 
To investigate the reason for aggregation, non-reducing SDS-PAGE experiments were 
performed. Non-reducing SDS-PAGE showed three major bands, with estimated sizes 
corresponding to monomer, dimer and aggregates, while the reduced SDS-PAGE showed 
only one band corresponding to a monomer (Figure II.9 a). Fraser J et al. reported two 
reduced cysteines (Cys597 and Cys620) in E2 protein are essential for virus entry (Fraser et 
al., 2011). The free cysteines might form intermolecular disulfide bonds and cause protein 
aggregation. To verify this, a Blue Native PAGE experiment was performed. Prior to 
electrophoresis, 0.1-1.5 mM DTT was added to protein samples and incubated at 4 °C for 3 
hours. However, the present of different concentrations of DTT did not solve the aggregation 
problem as the smeary and broad bands still indicated high aggregation (Figure II.9 b). In 
addition, two reduced cysteines (Cys597 and Cys620) were mutated into serines to avoid the 
intermolecular disulfide bonds (data not shown). Unfortunately, this did not help either. 
Taken together these results, the transient expressed HCV sE2 form aggregation, and the 
aggregation problem can not be solved by adding reducing agent or mutation, thus 
homogeneous sE2 can not be obtained by this method and the crystallization experiment 
could not be performed. 
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Figure II.9: Non-reduced SDS-PAGE and Blue Native PAGE analysis of E2 aggregation. (a) SDS-PAGE 
of reduced sE2 and non-reduced E2 ETD; MW: high molecular weight prestained protein marker (Thermo 
scientific). (b) Blue Native PAGE of E2 ETD in the presence of serial concentrations of DTT (0 - 1.5 mM); MW: 
high molecular weight Native PAGE marker. 
At the same time, a stable cell line expressing sE2 was constructed with the help of Dr. Joop 
van den Heuvel. The stable cell line was derived from a CHO Lec3.2.8.1 cell line. CHO 
Lec3.2.8.1 synthesizes glycoproteins with truncated carbohydrates, which have enabled the 
crystallization of many glycoproteins. Its protein products are glycosylated with high 
mannose type N-linked glycans (Wilke et al., 2010).  
His6-tagged sE2 was secreted by a stable cell line. The successful construction of this stable 
cell line was confirmed by Western blot using anti-His antibodies. sE2 has been purified with 
Ni-NTA affinity chromatography and followed by cation exchange chromatography. The 
purified protein was later applied onto a Superdex 200 10/30 column. Fortunately, sE2 
behaves as a monomeric protein on size exclusion chromatography (~ 50 kDa, Figure II.10 a).  
The protein has been further confirmed by N-terminal sequencing. The peak fractions of  size 
exclusion chromatography were collected and deglycosylated with EndoHf. A further size 
exclusion chromatography was performed with Superdex 75 10/30 column (higher resolution) 
to remove EndoHf and glycans. Deglycosylated sE2 stays as a monomer and appears as a 
homogenous protein (~ 35 kDa) on SDS-PAGE. Deglycosylated sE2 was concentrated and 
used for crystallization experiments. Unfortunately, crystallization setups did not yield any 
crystals with commercial screens, even after several rounds.  
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Figure II.10: Size exclusion chromatography of HCV sE2 expressed by a CHO lec 3.8.2.1 stable cell line. 
(a) Size exclusion chromatography with Superdex 200 10/30 column of sE2 and SDS-PAGE result, P1: protein 
sample after affinity purification; P2: protein with peak fraction of size exclusion chromatography. (b) Size 
exclusion chromatography with Superdex 75 10/30 of deglycosylated sE2 and SDS-PAGE result. P’: peak 
fraction of size exclusion chromatography; MW: unstained low molecular weight protein marker. Black arrows 
indicate bands of sE2 protein. 
A baculovirus-insect cell system was also used for His6-tagged sE2 expression. A 
recombinant baculovirus carrying the sE2 gene was successfully constructed. However, no 
expression was detected in the baculovirus infected insect cells (data not shown). 
II.3.2 SRB1 expression and characterization 
Scavenger receptor class B type I (SRB1) has been identified as one of the HCV receptors 
(Scarselli et al., 2002). It is a transmembrane protein that belongs to the CD 36 family. The 
extracellular domain is predicted to contain 9 N-glycosylation sites and three intramolecular 
disulfide bonds (Calvo and Vega, 1993; Krieger, 2001; Zeisel et al., 2007). Here the 
extracellular domain of SRB1 (residues 33 - 433) was cloned and expressed by two different 
strategies: transient expression and baculovirus-insect cell expression systems. 
In the initial transient expression tests with HEK 293 6E cells, SRB1was fused with a His6-
tag and cloned into the pFlpBtM II vector. But almost no expression was detected from the 
transfected cell supernatant. A pYD11 vector that included a C-terminal Fc coding sequence 
was selected to improve the protein yield. The SRB1 extracellular domain was inserted into 
the pYD11 vector, and transiently transfected into the HEK 293 6E cell line. Kifunensine was 
added to the culture to reduce the glycosylation complexity. Fc fusion SRB1 (SRB1-Fc) was 
purified with a protein A affinity column. SRB1-Fc has a theoretical size of 75 kDa, but due 
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to glycosylation, it shows a band around 110 kDa on SDS-PAGE (Figure II.11 a). HRP- 
conjugated goat anti-human IgG (Fc specific) antibodies were used for detecting SRB1-Fc 
expression in the Western blot experiment.  The corresponding bands were visualized on a 
PVDF membrane after 10s of exposure time with a LAS 3000 imager system (Figure II.11 b). 
SRB1-Fc expression was further verified by N-terminal sequencing in house. Compare to low 
expression of His6-tagged SRB1, Fc fusion SRB1 has a very high yield of about 7 mg per 
liter culture. However, it has the same aggregation problem as HCV sE2 protein. Due to high 
aggregation, the Fc fragment couldn’t be cleaved off by PreScission protease.  
 
Figure II.11: SDS-PAGE and Western Blot SRB1-Fc. (a) SDS-PAGE of SRB1-Fc after affinity purification; 
(b) Western Blot of SRB1-Fc using HRP- conjugated goat anti-human IgG (Fc specific) antibodies.   
Another attempt was to express and crystallize SRB1 single domains. Limited proteolysis 
was performed to define domain borders with purified SRB1-Fc. Different concentrations of 
pepsin, trypsin and chymotrypsin were incubated together with SRB1-Fc at RT for 30 min. 
Limited proteolysis yielded 3 cleavage sites inside SRB1-Fc. One common cleavage site is 
the border between SRB1 and Fc fragment. The other two cleavage sites divided the SRB1 
extracellular domain further into 3 domains: domain 1, residues 1 - 306; domain 2, residues 
307 - 352; domain 3, residues 353 - 433 (Figure II.12). Domain 1 has also been cloned into 
the pYD11 vector and transiently expressed similar to the full-length SRB1 ectodomain. 
Unfortunately, the purified product of domain 1 still shows strong aggregation (Data not 
shown). 
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Figure II.12: Limited proteolysis of transiently expressed SRB1-Fc. Limited proteolysis of SRB1-Fc has 
been performed with 3 different concentrations (1 μg/μl, 0.1 μg/μl and 0.001 μg/μl) of pepsin, trypsin and 
chymotrypsin at RT for 30 min. Black arrows indicate the protein band cut for N-terminal sequencing. 
Another expression strategy for SRB1 uses the baculovirus-insect cell system. Human SRB1 
(residues 33 - 433) was cloned into the pFlpBtM II donor vector. Recombinant bacmids were 
generated using the Tn7 transposition method in bacmids of the EMBacY (MBY) system, 
which includes a YFP-gene as a maker for infection monitoring (Meyer et al., 2013; 
Trowitzsch et al., 2010). Sf21 was infected with P1 (passage one) baculovirus. Three days 
after infection, the cell culture was harvested and cells were lysed for protein purification. N-
terminally strep-tagged SRB1 (strep-SRB1) ectodomain has been expressed and purified with 
a strep-tactin affinity column (Figure II.13 a). After affinity column, the protein was further 
purified with an anion exchange column. The purification product was visualized as a single 
band with a size of around 55 kDa on SDS-PAGE. Mass-spectroscopy and N-terminal 
sequencing confirmed strep-SRB1 expression and purification. Strep-SRB1 behaves as a 
monomer in size exclusion chromatography. However, the expression and purification 
experiments only succeeded once. During later infection trials with the same recombinant 
baculovirus, only a very small amount of protein was obtained. Due to insufficient amount of 
material, crystallization of SRB1 protein was not pursued. 
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Figure II.13: Purification of strep-SRB1 from insect cells. (a) SDS-PAGE analysis of affinity 
chromatography purification products, 1: protein sample purified with strep-tactin affinity column. (b) Size 
exclusion of strep-SRB1 with Superdex 200 10/30 column, and the SDS-PAGE analysis of peak fractions. 12,13: 
peak fractions from size exclusion chromatography; MW: prestained high molecular weight marker. 
II.4 Discussion and outlook 
II.4.1 HCV envelope protein E2  
A stable cell line expressing HCV E2 ectodomain (384-656, sE2) has been successfully 
constructed. The protein purified from this expression system shows no aggregation, which 
indicates the properly fold protein. However, the purified and deglycosylated protein didn’t 
yield any crystals after many crystallization trials. Crystallization is a thermodynamic process, 
which is mainly driven by the entropy gain from the released water molecules upon 
crystallization. If the protein is too flexible, this gain is compensated by an entropy loss from 
the restricted movement of protein side chains and loops. As the result, the protein does not 
crystallize. If the flexible loops are removed in the first place, the protein might become 
crystallizable (Derewenda, 2004; Derewenda and Vekilov, 2006; Hayward and Lee, 2002). 
Hence, more attention should be put on the protein constructs. While we were struggling with 
getting sE2 crystallized, two structures of HCV E2 core domain structures have been solved. 
One E2 core structure is using engineered E2 core constructs to avoid flexible hypervariable 
loops (HVR1 and HVR2), and is solved in cooperation of neutralizing antibody AR3C [PDB 
code: 4MWF (Kong et al., 2013)]. Another E2 core structure is using shorter constructs 
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(residues 456 -656), and the Fab fragment of antibody 2A12 was used for co-crystallization 
[PDB code: 4NX3 (Khan et al., 2014)]. The difference between our sE2 protein and E2 core 
is that the latter lacks the N-terminal hypervariable regions 1 and 2 (HVR1 and HVR2, about 
80 amino acids). HVR1 and HVR2 were proved to be flexible by limited proteolysis and 
hydrogen deuterium exchange (Khan et al., 2014), methods that we didn’t perform with our 
sE2 protein. In our HCV sE2 constructs, both flexible HVR1 and HVR2 are included, which 
is probably the reason why we didn’t get crystals. Further, they used antibodies or antibody 
fragments to facilitate crystallization. Antibodies and antibody fragments have been utilized a 
lot as the crystallization “chaperones” to aid the structural determination of otherwise 
‘uncrystallizable’ or ‘undruggable’ target proteins. Another advantage for antibody mediated 
crystallization is that it can provide model-based phasing information (Griffin and Lawson, 
2011), since at the time we started there is no molecular replacement model available. 
Because we couldn’t get hands on such antibodies, this method has not been put into practice. 
 The expression strategy that Khan et al. and Kong et al. used is transient expression with 
adherent monolayer HEK cell lines (HEK293T-GnTI- and HEK293T) in supplement with 
kifunensine. Similar transient expression strategy has been used in our experiments; the only 
difference is that we used the suspension cell culture. Although the suspension cell culture 
could produce protein in large amount, the proteins always showed high aggregation, which 
is probably due to misfolding. Since HCV E2 folding is a slow process, which involves 
complicated posttranslational modifications such as glycosylation and forming disulfide 
bridges. It seems that the lower cell density and better nutrient accessibility in a monolayer 
cell culture is beneficial for the production of properly folded E2 protein. 
Both HCV E2 core structures are consistent with each other except that Kong et al.’s 
structure includes a N-terminal engineered fragment and three extra mapped disulfide bridges. 
The E2 core domain has a globular fold, consisting of mostly β-strands and random coils. 
Two pairs of β-strands are antiparallelly arranged in the middle, flanked by short helices, 
loops and β-strands (Figure II.14). Despite seven pairs of disulfide bridges, which cross-link 
loops, strands and helix, the E2 core domain consists of nearly 62% disordered structure. 
Further, six glycosylation sites are all located in loops and the glycans are highly flexible. 
Before the HCV E2 core structure has been solved, it had been speculated to be similar to the 
class II fusion protein of flavivirus. All class II fusion proteins have an elongated structure, 
consisting of mainly β-strands, and exist as homo- or heterodimers with membrane fusion 
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interface in neutral pH. Upon receptor binding or pH decrease in the environment, the protein 
undergoes self-rearrangement into stable trimers, exposing the fusion peptide and resulting in 
viral and host membrane fusion (El Omari et al., 2013; Li et al., 2013; Vaney and Rey, 2011; 
White et al., 2008). Due to the lack of extended organization and fusion peptide, HCV E2 
protein seems not belonging to the class II fusion proteins (Khan et al., 2014; Kong et al., 
2013). 
 
Figure II.14: Cartoon view of HCV E2 core domain structures from 4MWF and 4NX3, and superposition. 
(a) Cartoon view of E2 core domain from 4MWF; (b) E2 core domain from 4NX3, both (b) and (c) are colored 
from N terminus (blue) to C terminus (red), disulfide bridges are colored in gray; (c) Superposition of  two E2 
core structures, 4MWF is colored in light green, 4NX3 is colored in light pink; (d) Topology of HCV E2 core 
structure, adopted from Kong et al. (2013). 
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The determination of the HCV E2 core structure is a big progress in the HCV research. For 
further understanding of the HCV entry process, HCV E1 structure and E1E2 complex 
structure determination has been put on the agenda. The mapping of E2 broadly neutralizing 
epitopes provides new opportunities for HCV vaccine development(Khan et al., 2014). The 
structural information of HCV E2 core will finally lead to new drug design. 
II.4.2 Scavenger receptor class B type I 
SRB1 is expressed only in limited tissues, such as liver and steroidogenic tissues, where it 
mediates cholesteryl ester uptake from high-density lipoprotein (HDL) (Silver, 2004). With 
the assistance of Fc fragment of IgG, SRB1 was highly expressed in transiently transfected 
HEK293 6E cell culture. Similar to HCV E2, HCV human receptor SRB1 is highly 
glycosylated and the transiently expressed protein had a high proportion of aggregates. In the 
baculovirus-insect cell expression system, homogenous SRB1 ectodomain has been obtained 
for the first time in small-scale culture. However, due to the unknown reason, almost no 
protein has been obtained in the larger scale infection trials, even with reconstructed 
recombinant baculovirus.  
Since monolayer cells could produce properly folded protein, using monolayer cell culture 
for transient transfection and expression might solve the aggregation problem. The transient 
expression strategy is more efficient in protein production than in insect cells. The later 
exploration of SRB1 structure should consider monolayer cell culture for the transient 
transfection and expression. Because Fc fragment could assist protein folding and improve 
protein solubility, the Fc fusion SRB1 constructs could be kept in future. It is also necessary 
to optimize the ectodomain constructs, for example, knock out flexible loops and crystallize 
separate domains.  Another strategy for co-crystallization with HCV E2 core protein could 
also be tried. 
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III.1 Introduction 
Legumain (EC=3.4.22.34) belongs to the cysteine proteases clan CD, family C13 (Chen et al., 
1998). Legumain is structurally related to caspases and is considered to be an asparaginyl 
endopeptidase because it specifically cleaves after asparagine at pH 5.8 (Chen et al., 2000; 
Liu et al., 2012). It has also been reported to cleave after aspartate residues at lower pH (pH 
3.0) (Chen et al., 1997; Halfon et al., 1998). Legumain is well conserved in plants, 
invertebrate parasites and mammals. Mammals have been found to show ubiquitous legumain 
expression with the highest levels in kidney, placenta, spleen, liver and testis (Yamane et al., 
2002). Mammalian legumain is considered to function in immunity and signal transduction. It 
has also been proposed to be essential in processing microbial antigens for class II 
histocompatibility complex (MHC II) presentation (Manoury et al., 1998) and in processing 
of cathepsin B, L and proMMP-2 into their active forms (Chen et al., 2001; Maehr et al., 
2005; Shirahama-Noda et al., 2003; Smith et al., 2012). Legumain has also been expressed at 
a high level in bone marrow. It blocks the later stages of osteoclast formation and regulates 
bone resorption (Choi et al., 1999). Recently, legumain has been found to be up-regulated in 
a number of diseases, such as atherosclerosis, stroke, and cancer. Overexpression of legumain 
was demonstrated to promote cell migration, invasion, and angiogenesis (Edgington et al., 
2013; Liu et al., 2003; Luo et al., 2006; Murthy et al., 2005; Ohno et al., 2013). Within the 
tumor microenvironment, cells that express high levels of legumain are tumor-associated 
macrophages (TAMs), but not tumor cells themselves (Luo et al., 2006). Based on this 
property, legumain has been selected as an anti-tumor target for anti-tumor vaccines in future 
cancer treatment (Lewen et al., 2008; Luo et al., 2006). 
The Chinese hamster legumain gene encodes a pre-protein of 438 amino acids (Xu et al., 
2011). It shares 83.1% sequence identity with human legumain. After cleavage of N-terminal 
signal peptide (residues 1 - 20) an inactive prolegumain (residues 21 - 438, ~56 kDa) is 
produced. In the cytoplasmic and nucleic environment, prolegumain could perform 
proteolytic maturation into its active form asparagine endopeptidase (AEP) by pH shift. 10 
residues at the N-terminus was further cleaved off, an activation peptide (AP, residues 297 - 
337) was further cleaved and released, and a less active legumain ACP (asparaginyl 
carboxypeptidase, ~ 50 kDa) was produced. In significantly lower pH (lysosome and 
endo/lysosome), highly active AEP (residues 31-291, ~35kDa) was produced through release 
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of the C-terminal legumain stabilization and activity modulation (LSAM, residues 337 - 436). 
In an extracellular environment, prolegumain could be loaded onto αVβ3 receptors, where the 
first proteolytic activation to ACP takes place. A second proteolytic activation could be 
performed with integrin stabilized ACP into integrin stabilized AEP. The intracellular and 
extracellular legumain could participate in different signal pathways, antigen processing and 
other protein processing (Dall and Brandstetter, 2013). The multiple functions and multiple 
locations of legumain are shown in Figure III.1. 
Interestingly, it has been discovered recently that the proteolytic activation of AEP is a 
reversible process. Partially activated AEP could be reversed back to its proenzyme form 
when the protein buffer pH shifted from acidic to neutral (Zhao et al., 2014). Legumain 
activity can be inhibited by cystatin C, E, M and ovocystatin (Alvarez-Fernandez et al., 1999), 
which inhibit through competitive binding of asparagine peptide to the active site (Zhao et al., 
2014). 
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Figure III.1: Multiple functions and multiple locations of legumain. After its posttranslational modifications 
within the Golgi apparatus and vesiculation, prolegumain can be either released into cytosol or loaded onto αVβ3 
integrin receptors. In an intracellular environment, transfer/fusion of prolegumain with lysosomal compartments 
will result in electrostatic release, and subsequent cleavage into AEP. In an extracellular environment, integrin 
stabilized AEP could be achieved by steps of proteolytic activation, as is necessary for its extracellular tasks 
(white box). Figure adapted from Dall and Brandstetter (2013). 
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III.2 Results 
III.2.1 Legumain structure determination 
During our experiment of constructing stable cell lines expressing HCV sE2 with the CHO 
lec 3.8.2.1 cell line, we found it constitutively secreting large amount of prolegumain into the 
culture media. The secreted prolegumain has a high binding ability for Ni-NTA, protein A 
and strep-tactin resins. Prolegumain was purified from CHO lec 3.8.2.1 cell supernatant with 
a series of purification steps (Ni-NTA affinity, anion exchange and size exclusion 
chromatographies). The size of prolegumain after anion exchange chromatography appeared 
to be around 57 kDa. After size exclusion chromatography with a pH 5.4 buffer, a smaller 
band appeared which indicated a portion of prolegumain undergoes self-cleavage. 
Prolegumain was deglycosylated in a pH 5.4 buffer, in which deglycosylation and auto-
cleavage happened simultaneously. After deglycosylation, another size exclusion 
chromatography was used to remove impurities. Finally, a protein of 37 kDa was yielded in 
situ, which is the active legumain (asparaginyl endopeptidase, AEP) (Figure III.2 a). 
Glycosylated HCV-sE2 high mannose protein has a size around 55 kDa, and the 
deglycosylated protein has a size about 35 kDa. In the beginning, the prolegumain and 
legumain were mistaken for HCV sE2 protein, but later the N-terminal protein sequencing 
rectified this. The 37 kDa legumain was used for crystallization experiments, and resulted in 
rod-shaped crystals (Figure III.2 b).  Crystals were obtained from three conditions: Condition 
1 contained 0.03M MgCl2, 0.03M CaCl2, 10% PEG 20 000, 20% PEG550 MME and 0.1 M 
MOPS/HEPES buffer, pH 7.5; condition 2 had similar ingredients with condition 1 but had a 
buffer pH of 8.0; condition 3 contained 0.1 M NaCl, 23% PEG 3350 and 0.1 M MOPS buffer, 
pH 6.5. Crystals were named legumainpH7.5, legumainpH8.0 and legumainpH6.5 respectively 
according to the pH of crystallization.  
Complete X-ray diffraction data were collected at wavelengths of 1.033191 Å at beamline 
P11 of PETRAPETRA III Hamburg, Germany. Data were processed with the XDS package 
(Kabsch, 2010). Three different space groups P212121, P3221 and P61 were obtained from 
legumainpH7.5, legumainpH8.0 and legumainpH6.5 crystals respectively. Molecular replacement 
(MR) was carried out with Phaser_MR against human legumain (PDB code: 4AWA) (Dall 
and Brandstetter, 2013). Prior to molecular replacement, non-conserved amino acid side 
chains of search models were pruned with Chainsaw. The log likelihood gain were 1524, 
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1579 and 3572 for datasets legumainpH7.5, legumainpH8.0 and legumainpH6.5, respectively. 
However, additional unmodeled electron densities were observed for legumainpH7.5 and 
legumainpH8.0 during manual building with Coot. These two datasets were again using MR 
against human prolegumain (PDB code: 4FGU). Surprisingly, the log likelihood gain values 
were more than doubled, and the electron density maps were properly interpreted. These two 
crystal forms (legumainpH7.5 and legumainpH8.0) were shown to contain the different protein 
prolegumain, which is the zymogen of active legumain. Matthew’s coefficients indicate each 
crystal form consists of only one molecule per asymmetric unit. The solvent contents of the 
three crystal forms are between 31% and 37%. LegumainpH7.5 crystals have a Wilson B-factor 
of 30.3 Å whereas legumainpH8.0 crystals have a higher value of 40.4 Å. LeguaminpH6.5 
crystals have a Wilson B-factor which is lower than 20 Å. LegumainpH7.5 and legumainpH8.0 
have similar highest resolution limit of 2.4 Å and 2.3 Å, respectively. The crystals of 
LeguaminpH6.5 diffracted beyond 1.5 Å resolution. The initial models for the three crystal 
forms were improved by iterative steps of manual building in Coot and refinement in 
Phenix.refine. Refinement was stopped after converging values of Rwork and Rfree were 
reached. The values of Rfree / Rwork are within the good range for datasets resolution and 
applied refinement strategies (Tickle et al., 1998). More than 97 % of the residues lie in the 
most favored region of the Ramachandran diagram in all three structural models. Data 
collection and refinement statistics for the three crystal forms are summarized in Table III.1.  
Figure III.2: Purification and crystallization of legumain. (a) SDS-PAGE analysis of purified prolegumain 
and its deglycosylation and auto-activation. 1: Prolegumain after anion exchange chromatography; 2: size 
exclusion chromatography in pH 5.4 buffer indicates partial auto-cleavage; 3: Deglycosylated and auto-
activated legumain; MW: low molecular weight protein marker. (b) Crystal of legumain at pH6.5. 
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Table III.1: Data collection and refinement statistics of legumain crystals 
Data statistics  legumainpH7.5 legumainpH8.0 legumainpH6.5 
Space group P 21 21 21 P 32 2 1 P 61 
Cell constants a, b, c (Å) 38.3, 60.3, 154.0 50.8, 50.8, 253.6 43.6, 43.6, 209.6 
                        α, β, γ (°) 90, 90, 90 90, 90, 120 90, 90, 120 
Mol. / a.s.u. 1 1 1 
Wilson B-factor (Å
2
) 30.3 40.4 19.2 
Solvent content (%) 31.3 35.4 36.5 
Resolution range (Å) 20.0-2.4 (2.49-2.40) 20.0-2.3 (2.38-2.30) 20.0-1.5 (1.55-1.50) 
I/σ(I) 11.3 (2.4) 16.5 (2.8) 13.0 (2.18) 
Completeness overall (%) 100.0 (99.9) 100.0 (100.0) 100.0 (100.0) 
Unique Reflections 14574 (1401) 17828 (1717) 35874 (3570) 
Multiplicity 11.8 (12.0) 17.7 (17.8) 6.6 (5.0) 
Rmerge (%) 22.6 (78.4) 2.6 (23.8) 3.3 (36.3) 
Wavelength (Å) 1.033191 1.033191 1.581827 
Refinement Statistics     
Rwork (%)  20.7 (27.5) 20.2 (27.9) 17.6 (28.3) 
Rfree (%) 25.0 (33.0) 24.0 (28.0) 20.6 (30.0) 
av. B-factor of protein atoms(Å
2
) 35.1 49.4 32.7 
r.m.s.d. bonds (Å) / angles (°) 0.003 / 0.78 0.003 / 0.79 0.012 /1.48 
Ramachandran favored (%) 98.0 97.0 98.0 
Ramachandran allowed (%) 1.47 2.48 1.62 
 (): Values in () correspond to the highest resolution shell. 
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III.2.2 Prolegumain structures 
Although we intended to set up crystallization screens with cleaved legumain, two crystal 
forms from legumainpH 7.5 and legumainpH 8.0 were interpreted to include the C-terminal cap, 
and the protein content is Chinese hamster prolegumain (PDB code: 4FGU). Similar to 
human prolegumain, the Chinese hamster prolegumain also possesses three domains: an AEP 
core domain (cyan, Ala26 - Met286), an activation peptide (AP, orange, Lys287 - Leu331) 
and a legumain stabilization and activity modulation domain (LSAM, slate, Val332-Ser431) 
(Figure III.3). The AEP core domain is composed of 6 well-aligned β-strands flanked by five 
major α-helices and loops. The LSAM domain is composed of five α-helices, which have a 
death domain like fold (Dall and Brandstetter, 2013), and two pairs of disulfide bridges for 
stabilizing the helices. The LSAM domain behaves like a cap covering the top of AEP, which 
prevents the substrate from accessing the active site.  The AP fragment includes a N-terminal 
loop and a C-terminal helix. In prolegumain, AP binds to the active site in a substrate-like 
way and blocks access of true substrate to the active site (Dall and Brandstetter, 2013).  
 
Figure III.3: Organization of legumainpH7.5 and legumainpH8.0. Structural domains are colored differently, 
LSAM domain: slate; AP fragment: orange; AEP core: cyan. The gaps in structural models are marked as Gap 1 
and Gap 2. 
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Figure III.4: Electrostatics of legumain domains. Blue represents positive potential, and red represents 
negative potential. The active site surface of the AEP core domain is highly negative charged and colored in red. 
The electrostatic surface potentials are mapped onto Van-der-Waals surfaces (red: negative, blue: positive, 
white: neutral). 
Compared to the full-length human prolegumain structure, two gaps have been found in the 
Chinese hamster legumainpH7.5 structure (Figure III.3 a). Gap 1 (Leu324 - Leu336) contains 
the β-cleavage site at Asn328 - Asp329 and Gap 2 (Met282 - Lys292) contains the putative α-
cleavage site (Asp308). The gaps are also the domain borders between the AEP domain, AP 
fragment and LSAM domain. The difference of legumainpH7.5 from legumainpH8.0 is that Gap 
2 is not present in the former. Based on the reverse autoproteolytic theory (Zhao et al., 2014), 
legumainpH7.5 and legumainpH8.0 are two intermediates before complete reversal back to full-
length prolegumain.  This could indicate that the reversible autoproteolytic process is 
performed in steps during pH shifts from acidic pH to basic pH. During an increase in pH, the 
three domains of legumain are attached together through electrostatic interactions, ligation of 
the AP fragment is followed by ligation of LSAM to finally produce the prolegumain. The 
LSAM domain and AP fragment interact with the AEP core domain through numerous 
hydrogen bonds and salt bridges. Electrostatic analysis shows legumain is a highly charged 
molecule; the surface potential charge of AEP core domain at the active site is extremely 
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negative. Under neutral and basic conditions, the surface potential charge of LSAM domain 
and AP fragment could complement the negative charge on the active site surface and keep 
the protein intact. Under acidic conditions, the active site surface is protonated and the 
LSAM domain and AP fragment would dissociate (Figure III.4). Without the ligation 
between domains in legumainpH7.5, three domains could still hold together in the inactive 
form as prolegumain. The LSAM domain and AP fragment behave like a cap that covers the 
active surface of the AEP core and prevents the substrate from accessing the active site in 
neutral and basic pH. 
III.2.3 LegumainpH6.5 structure 
A high-resolution dataset with the lowest resolution limit of 1.5 Å was obtained for 
leguaminpH6.5, which allowed us to view the active site in detail. The crystal structure of 
Chinese hamster active legumainpH6.5 showed similar architecture to the human AEP structure 
(Dall and Brandstetter, 2013). There are six β-strands (β1, β2, β3, β6, β7, β8) in a parallel 
arrangement in the center, surrounding by five major α-helices (α1, α2, α4, α7, α8). The 
residues that are critical for the AEP activity are located on α1, a loop between β3 and β4, 
and a loop between α5 and β6. Legumain is also N-glycosylated where all three glycosylation 
sites are located in the AEP core. Two glycosylation sites NAG2 and NAG3 (linked to 
Asn172 and Asn 277 respectively) clearly showed a 100% occupancy in electron density map 
during refinement, while NAG1 (linked to Asn 96) showed a lower occupancy (Figure III.5).  
III.2.4 A Succnimide and a S-oxy cysteine in the active site 
The catalytic site sits in a pocket on the surface of the AEP core domain and is covered by the 
LSAM domain in prolegumain. Asn42, His148 and C189 are reported as key residues for 
legumain activity (Dall and Brandstetter, 2013). Correspondingly, Asn44, His150 and 
Cys191 are key residues for mouse AEP activity. In addition, Arg46, Glu189, Ser217, Ser218 
and Asp233 are also reported to be essential for mouse AEP activity. In Chinese hamster 
legumain, Asn47, His153 and Cys194 are critical residues for legumain activity. In our 1.5Å 
resolution structure, we found Asp152, which is located next to His153, was cyclized to a 
succinimide (SNN) residue, and Cys194 (cysteine) was oxidized to S-oxy cysteine (CSX) 
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(Figure III.6 a and b). The detailed structure of the active site will be discussed in the next 
chapter. 
 
Figure III.5: Stereo view of legumainpH6.5 structure and special residues. (a) Stereo view of legumainpH6.5 α-
helices and β-strands are numbered; key residues for the AEP activity are shown as sticks.  α-Helices are 
colored palegreen, β-strands are colored skyblue and loops are colored light orange; (b) close view of residue 
succinimide (SNN152); (c) close view of S-oxy cysteine (CSX194). 
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III.3 Discussion and outlook 
During purification of HCV sE2 from CHO stable cell line supernatant, a protein yielded the 
same band (~55 kDa) as HCV sE2 on SDS-PAGE was co-purified together with sE2 with 
affinity chromatography. In the acidic deglycosylation buffer (pH 5.4), the protein decreases 
its size to 35 kDa, which is similar to size of deglycosylated sE2 protein (~ 33 kDa). This 
protein was initially mistaken as HCV sE2, but later it was proved to be Chinese hamster 
legumain with N-terminal protein sequencing method. The 55 kDa protein is the zymogen of 
legumain and is called prolegumain. In deglycosylation buffer, prolegumain performs self-
cleavage and deglycosylation, which removes the C-terminal fragment and N-glycans. After 
self-cleavage of C-terminal fragment, the protein turns into active asparaginyl endopeptidase 
legumain. Legumain was further purified with a size exclusion chromatography and gave out 
rod-shape crystals in crystallization screens. So to speak, the Legumain crystals are 
byproducts of HCV E2 project. 
Two forms of prolegumain structures were obtained, both of which are similar except the α- 
cleavage site (KRK
291
) and β- cleavage site (N325D326). The superposition of legumainpH7.5 to 
human prolegumain (4AWA) and mouse prolegumain (4NOM) showed a slight 
inconsistency in the AEP domains (Figure III.7). The main differences are the LSAM 
domains, which shift slightly in three structures. The r.m.s. derivations between legumainpH7.5 
and 4AWA is 2.2 Å, and the value is 2.0 Å with 4NOM. One active legumain (AEP) 
structure was also solved with very high resolution at 1.5 Å. An aspartate residue next to 
His153 was cyclized into a succinimide. Checking the electron density maps of legumain 
active sites from structures published by Dall & Brandstetter (2013). (Figure III.6 b) and 
Zhao et al. (2014) (Figure III.6 c), we found that aspartate does not fit properly into the 
electron density where succinimide should fit. Succinimide was reported to be the 
intermediate from aspartyl and asparaginyl peptides during spontaneous protein degradation 
(Geiger and Clarke, 1987; Stephenson and Clarke, 1989). Since the cyclic succinimide was 
found in all legumain structures and seems to be stable in physiological conditions, the 
presence of succinimide here should not contribute to AEP degradation. It is assumed that the 
formation of succnimide is due to the highly negative charged and hydrophobic environment, 
which results in dehydration and cyclization of aspartate.  
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Figure III.6: Key residues in the active site of AEP from different organisms. Stereo views of legumain 
active sites, key residues are shown as sticks, the refined electron density map 2Fo-Fc (contoured at 1σ) is 
shown as a blue mesh, Fo-Fc map (contoured at 3σ) is shown as a green mesh. (a) Active site of legumainpH6.5; 
(b) active site of mouse legumain 4NOK; (c) Human legumain 4AW9 with ligand binding, ligand is shown in 
pink sticks; (d) The hydrophobic environment of SNN152. SNN152 is shown in orange and blue sticks, the 
surrounding residues are shown in yellow and blue sticks. 
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The succinimide in the active site provides a more rigid conformation, which is necessary for 
enzyme specificity, than an aspartate residue.  
Further, in mouse legumain structure (4NOK), cysteine residue has a positive triangle feature 
in the Fo-Fc map, which might be a S-oxy cysteine (CSX) with alternate conformations. In 
our structure, we built two alternate conformations of S-oxy cysteine (CSX) in the Cys194 
position. Since the reaction from cysteine to CSX is irreversible, CSX is impossible to 
participate in the protease reaction, so the oxidization of cysteine might be an artifact of the 
crystallization process. 
One thing that makes people confused is the α- and β- cleavage sites of prolegumain. In the 
legumainpH7.5 structure model, both cleavage sites are open, which could be explained as 
electrostatic interaction on the domains’ interface. In acidic pH the three domains expel each 
other, but in neutral and basic pH, these three domains attach together and go back to its 
original position and shield the active site. In legumainpH8.0 structure, the α-cleavage site is 
still ligated. This could due to the incomplete cleavage before crystallization experiment. 
Another explanation from Zhao, et al. is the reversible autoproteolysis. During pH shift from 
acidic to neutral, three domains assemble together to form an inactive prolegumain before 
“healing” of peptide bonds. That of the α-cleavage site follows the healing of the β-cleavage 
site. As is commonly known, the peptide bond forming needs energy, but in the pure protein 
system, no energy is involved. Also the SDS-PAGE experiment couldn’t confirm the split 
fragments is ligated by peptide bonds, which might be ligated by other covalent bonds. The 
reversible auto proteolysis theory needs more evidence to prove the “healing” of peptide 
bonds. 
The prolegumain structures that have been solved in this work could still be the evidence for 
the auto maturation process from preprolegumain to active legumain. The auto maturation 
process could be summarized as in Figure III.7 b. The preprolegumain was translated on 
ribosome. N-terminal signal peptide (residues 1 - 20) was cleaved off by posttranslational 
modification, and an inactive prolegumain was translocated into lysosome or secreted into 
cytosol. In slightly acidic pH, the N-terminal was further cleaved by 10 residues (residues 21 
- 29), and the C-terminal LSAM (residues 337 - 436) domain was self-cleaved off. In even 
lower pH or with longer incubation time, the AP fragment was further cleaved off (residues 
297 - 337), yielding a highly active legumain AEP. The structural information of legumain 
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and its auto activation mechanism could be used for vaccine development and drug design in 
anti-cancer research. 
 
Figure III.7: Superposition of the mouse prolegumain (PDB code: 4NOK) and legumainpH7.5 and 
illustration of auto proteolytic process. (a) Superposition of mouse prolegumain and legumainpH7.5. Mouse 
prolegumain is colored in gray. LegumainpH7.5 is colored in domains. (b) Illustration of maturation process of 
preprolegumain into legumain. 
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IV Materials and Methods 
IV.1 General background knowledge and methods for crystallography 
IV.1.1 Vapor diffusion 
In order to obtain X-ray diffraction map for X-ray crystallography, a well ordered protein 
crystal is needed. Crystal formation is principally an energetically favored process: a 
crystalline structure was formed from a fluid, Entropy is gained due to the loss of the ordered 
hydration shell surrounding the protein molecules upon nucleation and further adsorption of 
protein molecules to the seed, and the free energy in the local environment decreases. The 
crystallization process mechanically consists of two processes: nucleation and crystal growth. 
For both, the supersaturation state is the prerequisite, and it can be reached through shift of 
protein concentration and precipitant concentration according to the phase diagram (Figure 
IV.1). 
 
Figure IV.1: A schematic phase diagram for protein crystallization. A solubility curve is drawn in black line 
between yellow and dark blue region. The dots from 1 to 3 indicate the crystallization process: upon the increase 
of protein concentration or precipitant concentration, protein molecules reach supersaturation zone and start 
nucleation; crystals start growing on nucleus and stop growing when protein in solution reaches solubility curve. 
(Asherie, 2004; Lukat, 2011). 
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Nucleation is the process where the solute molecules scattered in solvent start to gather into 
clusters, which keep stable under the current operating conditions for a short instant. These 
stable clusters constitute the nuclei (Figure IV.1, point 2) for more protein molecules 
adsorption and lead to crystal growth. During crystal growing, the protein concentration in 
solution decreases, after reaching the solubility curve, the crystal stops growing (Figure IV.1, 
point 3). 
The most common artificial method for producing crystals is called vapor diffusion, which is 
usually performed as hanging drop or sitting drop in laboratory (MacPherson, 1982). The 
reservoir liquid contains precipitants such as polyethylene glycols, alcohols and salts that 
reduce the solubility of protein. A drop of purified protein solution is mixed with a drop of 
reservoir solution on a cover slide. The slide is inverted over the well and sealed with grease 
to form a closed environment with reservoir solution. The protein concentration in the drop 
increases due to vapor leaving in order to reach equilibrium with its surroundings (Figure 
IV.2). During this process, the protein concentration will be brought into supersaturation state 
and crystals might appear. 
 
 
Figure IV.2: Schematic representation of 
the vapor diffusion method. A hang drop 
method was shown as an example 
. 
IV.1.2 Cryocrystallography 
As X-rays have short wavelength electromagnetic spectrum (mostly from 0.01 to 10 nm) and 
carry high photon energies, X-ray photons could ionize atoms and disrupt molecular bonds 
easily. Due to this radiation damage, the diffraction quality of protein crystals will decay 
upon X-ray exposure. Even more damages are caused by water radicals, which could diffuse 
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and contact with protein molecules and thus destroy the regular crystal lattice. To minimize 
these radiation damages and ensure high quality diffraction data, a proper cryo-protectant has 
to be found. Crystals protected by cryo-protectant are immobilized by flash freezing in liquid 
nitrogen, and kept cooled by a flush of nitrogen gas stream at 100 K during measurement. 
IV.1.3 Protein Quantitation 
For quick determination of protein concentrations, a Nanodrop Protein A280 program was 
used. The molar weight and molar extinction coefficient are important for the concentration 
calculation. Both parameters were given by Vector NTI 10.0 software (?). The molar 
extinction coefficient is determined at a wavelength of λ = 280 nm, at which protein 
molecules show a specific absorption peak according to their content of aromatic amino acid 
side chains. According to Lambert-Beer’s law (Beer, 1852), the absorption A of a protein 
molecule at a specific wavelength is proportional to its concentration c in the cuvette. The 
proportionality factors are the path length of the cuvette d and the extinction coefficient ε. 
A280 =  ε280  c  d 
Given the measured value of protein absorption at 280nm (A280), the protein extinction 
coefficient (ε280), and the known path length of the cuvette d, the protein concentration can be 
determined. 
IV.1.4 R factor 
In crystallography, the R factor (Rwork) is an evaluation of agreement between the atomic 
model and the experiment X-ray diffraction data. It is defined by the following equation: 
obs calc
obs
F F
R
F




 
where F is the structure factor and the sum extends over all the experimental measurements 
and the ideal calculated values. The structure factor is positively related to the intensity of the 
reflection. To avoid bias during refinement process, the Rfree value is introduced. Before 
refinement, about 10% of the observations are removed from the data set. Then the 
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refinement is performed with the left 90%. The Rfree is calculated to see the agreement 
between the predicted model and the 10% dataset that were not used in refinement (Brunger, 
1992). 
IV.1.5   Graphical representations 
Graphical representations of the protein structures were made using the program PYMOL 
(Schrödinger LLC, 2009). Molecular surface potentials were calculated using DELPHI 
(Honig & Nicholls, 1995; Rocchia et al., 2001). Sequence alignments were produced using 
CLUSTALW (Thompson et al., 2002) and plotted using ESPRIPT (Gouet et al., 1999). 
Chemical structures were drawn using CHEMSKETCH (Advanced Chemistry Development, 
Inc., 2006). 
IV.2  Yersinia glycolytic enzymes 
IV.2.1 Cloning and Expression 
YePykF and YePykA of Yersinia enterocolitica WA-314 were cloned according to a 
modified protocol published by our collaborator earlier (Hofmann et al., 2013). YePykF and 
YePykA gene were cloned into pWS plasmid and later transformed into Escherichia coli 
BL21 (DE3) pLysS competent cells. Positive colonies were selected and cultured in 2YT 
medium at 310k, 150 rpm overnight. The overnight culture was inoculated into 2 Liters of 
fresh 2YT medium with the percentage of 5%. The culture was shaking at 150rpm, 310k until 
OD600nm reached 0.6. Expression was induced by addition of 0.1mM of IPTG. After 5 hours 
of incubation at 300k, the culture was harvested by centrifugation at 6000 rpm for 10min and 
the pallet was resuspended in resuspension buffer [10 mM Tris pH 8.5, 50 mM KCl, 5 mM 
DTT, Complete Protease Inhibitor Cocktail (Roche Diagnostics GmbH)]. To disrupt cells, the 
resuspension was passaged through EmulsiFlex-C3 homogenizer (Avestin) three times. After 
centrifuging the cell lysate at 20 000g for 20min, the supernatant was filtrated through a 0.2 
μm sterile filters (Sartorius, Germany). 
IV.2.2 Protein purification 
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Non-tagged YePykF and YePykA were purified according to the protocol of our collaborator 
(Hofmann et al., 2013). A HiPrep16/10 Q XL column (GE Healthcare) was employed and 
equilibrated with 5 column volumes (CV) of buffer A (10 mM Tris-HCl pH 8.5, 50 mM KCl, 
1 mM DTT) on ÄKTA purifier system (GE Healthcare). After applying the supernatant, the 
column was washed with 10 CV of buffer A and eluted by a 20 CV linear gradient from 0% 
to 25% buffer B (10 mM Tris-HCl pH 8.5, 1 M KCl, 1 mM DTT).  The eluted fractions were 
collected and analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE). PykF, which has a PI of 6 based on the primary sequence, was eluted in a range of 
160-200 mM KCl. PykA with a PI of 6.8 was eluted in a range of 130-185 mM KCl. The 
fractions including PykF and PykA were pooled and concentrated with a Vivaspin 20 filter 
(Sartorius Stedim Biotech) with a cut-off of 30 kDa. 
A Superdex
TM
 200 HR 10/30 column (GE Healthcare) was equilibrated with buffer C (10 
mM Tris-HCl pH 8, 100 mM KCl, 1 mM DTT). 0.5 mL of concentrated protein (2% of 
column volume) was injected and loaded onto the column. The elution was carried on with 
the same buffer for 1.5 CV at a flow rate of 0.5 mL/min. The elutions were fractionated and 
analyzed by SDS-PAGE. Elute fractions including pure YePykF and YePykA were pooled 
and concentrated by Vivaspin 2 filter (Sartorius Stedim Biotech) with the cut-off of 30 kDa. 
The concentration of protein was determined with Nanodrop Protein A280 program as 
described before. Both proteins were adjusted to a concentration about 8 mg/ml for the 
crystallization test. 
IV.2.3 Thermoshift assay 
A 50µl testing system was set up in 96 well PCR plate. The system included 20mM Tris-HCl, 
pH 8.0, 100mM KCl, 10x SYBRO Orange (Invitrogen), 0.5 mg/ml YePykF or YePykA 
protein, 1 mM of the test ligand. In negative controls, no ligand was added. Common binding 
partners like pyruvate, oxalate and PEP were tested for both proteins. Additionally, ADP and 
F16BP were tested for YePykF, ribose 5-phosphate and AMP were tested for YePykA. The 
plate was sealed with optical quality sealer. The plate was slowly heated up from 283 K to 
363 K by 0.5 K increment. The excitation and emission wavelengths were 485 and 575 nm, 
respectively. The fluorescence signal was analyzed with CFX Manager software. 
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IV.2.4 Circular dichroism (CD) spectroscopy 
CD data of YePykF and YePykA were acquired on a Jasco J-815 CD spectrometer (Jasco, 
Inc) in house. Since F16BP was studied having the largest melting temperature shift and 
leads to the most stable conformation, YePykF+F16BP was also tested by CD spectroscopy. 
PykA (22 μM), PykF (10 μM), and PykF in the presence of F16BP (10 mM) were 
equilibrated in 20 mM Tris-HCl (pH 8.0) and measured at 283 K in a 0.1-cm path-length 
cuvette. Spectra were recorded in the 190-260 nm wavelength range with 1 nm increments 
(20 nm / min), 10 s averaging time, and 1 nm bandwidth for 10 repeats. The mean residue 
molar ellipticity was calculated by  
 
where Ө is the ellipticity in degrees, l the optical path in cm, C the protein concentration in 
mg/ml, M is the protein’s molecular mass, n the number of residues in the protein, and [Ө] 
the mean residue molar ellipticity in deg•cm2•dmol-1. The baseline-corrected spectra were 
used for protein secondary structure analysis. 
IV.2.5 Crystallization of YePykF, YePykF + FBP and YePykA + AMP 
Prior to crystallization setup, an ultracentrifugation was performed with freshly purified 
protein at 50 000 g for 20 min, at 277 k.  Sparse matrix sampling screens were set up with 
Honeybee system (Digilab, Inc., Marlborough, USA) in 96-well IntelliPlates (Art Robbins 
Instruments, Sunnyvale, USA) with sitting drop method. Both YePykF and YePykA were 
buffer exchanged into a buffer contains10mM Tris-HCl, pH 8.0, 100mM KCl, with 
concentration of 7.8 mg/ml and 8.2 mg/ml respectively. Protein and reservoir volume ratio 
was set to 1:1 (0.2 μl : 0.2 μl) with a total volume of 0.4 μl.  The sealed crystallization plates 
were incubated in 293 K and 285 K and later screened with Formulatrix Rock Imager 
(Formulatrix, Waltham, USA). 
In order to optimize crystal size and quality, a fine screen was set up. A hanging drop method 
was employed to yield lager drops with a volume ratio of 1μl to 1 μl.  24-well hanging drop 
Cryschem 24-1 SBS plates (Hampton Research, Aliso Viejo, USA) were used for designing 
the finescreen experiments based on the best initial hit conditions. Two parameters of the 
  nlCM  100
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crystallization condition were varied along X-axis and Y-Axis of the 24 well plates, while the 
other parameters were kept unchanged.  
Iterative matrix seeding was employed for PykF+FBP crystals and PykA+AMP crystals. A 
good quality crystal was selected from finescreen, and a seed - bead (Hampton Research, 
Aliso Viejo, USA) was used for smashing the crystal. First, 50 μl of reservoir solution was 
filled into a 1.5 ml Eppendorf tube including seed - bead. Secondly, a good quality crystal 
was fished out and washed once in 2 μl reservoir drop and later transferred to a new drop, 
which was then pipetted into the 1.5 ml Eppendorf tube containing the seed head. Thirdly, the 
1.5 ml Eppendorf tube including seed - bead and crystal and reservoir buffer was vortexed 5 
times and cooled down on ice. Every cycle include 30 seconds vortex and 30 seconds 
incubation on ice. Lastly, the 1.5 ml Eppendorf tube including smashed seeds was 
centrifuged at 12 000 g for 3 min to remove large particles. The seeds solution can be diluted 
in series and stored in -80 °C for a seeds stock. A 10 times serial dilution of seeds stock was 
made (0.1 μl of seeds solution was mixed with 0.5 μl of protein and 0.4 μl of reservoir 
solution) and used for seeding experiment.  The plates were incubated in 293 K or 285 K and 
crystals could be harvested in 2 - 4 days. 
IV.2.5.1 YePykF Crystallization 
Lenticular Crystals of YePykF appeared at 285 k 6 months after screen set up. The condition 
contains 1.6 - 2 M ammonium sulfate, 0.1 M Tris/HCl, pH 8.0. Because the crystallization 
process took too long time, no optimization was performed. A single apo YePykF crystal was 
cryo-protected in 3M ammonium sulfate, 10% glycerol, 0.1 M Tris/HCl, pH 8.0, and was 
quickly dipped into liquid nitrogen for later data collection experiment. 
IV.2.5.2 YePykF+F16BP Crystallization 
In order to co-crystallize YePykF and its effector F16BP (10mM fructose 1, 6-diphosphate) 
was added to 8mg/mL PykF right before crystallization set up. Crystals of PykF and F16BP 
complex appeared in conditions consisting of 19-25% PEG 6000, 0.2M Tris/HCl, pH 7.6, 
0.1M KCl at 293K. Tiny crystals can be observed under microscope 2-3 hours after plate has 
been setup. Finscreens were set up with pH shifted along X - axis from 7.0 to 8.0, while 
polyethylene glycol 6000 (PEG 6000) shifted along Y - axis from 18 % - 21%. 3 rounds of 
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matrix micro-seeding were performed, the reservoir solutions were set up with pH at 7.6, 
polyethylene glycol 6000 (PEG 6000) shifted along Y - axis of 24 - well plate from 16.5 % - 
18%, with 0.5% as a step. A single crystal was cryo-protected in a solution containing 30% 
PEG 6000, 0.2M Tris/HCl, pH 7.6, supplemented with 20% glycerol and was fast frozen in 
liquid nitrogen for later X-ray diffraction test. 
IV.2.5.3 YePykA+AMP Crystallization 
YePykA (8mg/ml) was mixed with its activator AMP (10mM) immediately before 
crystallization set up. 3 dimensional crystals appeared in conditions containing 35% 
Pentaerythritol ethoxylate (15/4 EO/OH), 0.2M CaCl2, 0.1M Tris/HCl, pH 8.0, at 285K. 
Finescreen was performed with pH shifted along X - axis from 6.0 to 9.0, and Pentaerythritol 
ethoxylate (15/4 EO/OH), Shifted along Y- axis from 29% to 34%. Matrix microseeding was 
performed with 26 % to 29 % Pentaerythritol ethoxylate (15/4 EO/OH). A single crystal was 
cryo-protected with 35% Pentaerythritol ethoxylate (15/4 EO/OH), 10% glycerol, 0.2M 
CaCl2, 0.1M Tris / HCl, pH 8.0 and was quickly frozen in liquid nitrogen for later X-ray data 
collection. 
IV.2.6 Structure determination 
IV.2.6.1 Data collection and processing 
X-ray diffraction data of PykF + FBP crystals were collected at beamline 14.2 of BESSY II 
( Helmholtz centrum Berlin, Germany) for 360° with a CCD detector at a wavelength of λ = 
0.918 Å. X-ray diffraction data of PykF and PykA + AMP crystals were collected at beam 
line P11 Petra III/DESY, Hamburg for 360° with a Pilatus 6M detector, at a wavelength of λ = 
1.033 Å. Data were processed with the XDS package (Kabsch, 2010), additional symmetry 
elements was evaluated by POINTLESS (Evans, 2006), unit cell content was analyzed by 
Matthews Coefficient (Matthews, 1968) from CCP4 software suite. 
IV.2.6.2 Molecular replacement 
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Molecular replacement of YePykF + F16BP was carried out with Phaser_MR (Adams et al., 
2010) against the monomer structure of E. coli PK (PDB ID: 1E0T). Non-conserved amino 
acids side chains of the search model were pruned with Chainsaw (Winn et al., 2011) prior to 
molecular replacement. The sequence identity of YePykF and E. coli PykF is 85.7 %. MR of 
YePykF was carried out against YePykF+F16BP structure. Molecular replacement was 
carried out against 2 ensembles. Ensemble 1 is domain B (from amino acid 71 to 167), 
ensemble 2 is YePykF+F16BP structure without B domain. MR of YePykA was carried out 
against YePykF-F16BP (36.7% sequence identity) structure as search model. MR model was 
produced by Chainsaw. Molecular replacement was also carried out against 2 ensembles. 
Ensemble 1 is the MR model domain B (residue 71 to 167), and ensemble 2 is MR model 
without domain B. 
IV.2.6.3 Model building and refinement 
The initial model was improved by iterative steps of manual building in Coot (Emsley and 
Cowtan, 2004; Emsley et al., 2010) and refinement in Phenix.refine (Adams et al., 2010). 
Rigid body refinement and restrained refinement of PykA+AMP was done using REFMAC5 
(Murshudov et al. 2011). Where appropriate, ligands (F26BP, SO4 groups), metal ions and 
water molecules were added to the structure. Atomic displacement factors (B) were treated as 
being isotropic. The presence of anisotropic domain movement was acknowledged by 
carrying out TLS refinement. Refinement was stopped after converging values of Rwork and 
Rfree were reached. The PK activity assays and kinetics study have been done by our 
collaborator from Robert Koch Institute. 
IV.3 HCV and human receptor interactions 
IV.3.1 Cloning and expression of HCV sE2 (HCV sE2) 
IV.3.1.1 Transient expression of HCV sE2 in HEK 293 cell line 
HCV (strain JFH1) soluble E2 (sE2, residues 384-661) was fused with a His6-tag and cloned 
into pcDNA 3.1-tpa eukaryotic expression vector. One-day prior transfection, HEK293-6E 
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cells were cultured in in F17 medium supplemented with 25 mg/L G418, 1 g/L Pluronic F86 
and 7.5 mM L-glutamine, cells were adjusted to a concentration of 1.0×10
6
 c/ml, with a 
culture volume of 500 ml. On the second day, cells were transfected with an optimized 
polyethylenimine PEI transfection procedure(Jager et al., 2013). 500 ng pcDNA 3.1 tpa-sE2 
plasmids mixed with 1250ng of PEI (polyethylenimine) in F17 medium, after incubation at 
room temperature for 15 - 30 min, the mixture were added to the cells. Together with 
transfection, 10μM kifunensine (α-mannosidases inhibitor) was also added to the culture. 
Cultures were fed 48 h post transfection with 0.5% trypton TN1 plus one additional volume 
of fresh F17 medium (kifunensine was also added up to 10μM). 4.5 g/ml glucose was added 
to the culture 72 h post transfection. 5 days after transfection, the cell supernatant was 
harvested and buffer changed with PBS for later Western Blot detection and affinity 
purification.  
IV.3.1.2 Stable cell line construction of HCV sE2 
HCV E2 ectodmain was cloned into pFlpBtM II vector (Genebank ID: KC991095) with 
restriction enzymes NheI and HindIII.  For stable transfection, 1.5 × 10
6
 cells in 2 ml medium 
were transfected with pFlpBtM II-sE2 plasmids by using the U-24 program of Amaxa 
nucleofection device according to the guidelines (Lonza, Co- logne, Germany). 24 hours after 
transfection, the medium was changed and the cells were seeded into six-well plates for 
culturing at 37℃，5% CO2, 110 rpm on an Incutec K15-500 linear shaker. In the following 
days, the cells were expanded and seeded in 8-cm cell culture dishes, white colonies were 
pipetted out and limited diluted into 96-well plate for cell line purifying. The cell culture 
supernatant was then analyzed by SDS-PAGE and Western Blot. Conditioned medium (20 L) 
was produced with verified stable cell line by continuous perfusion with a 2.5 L bioreactor. 
Cell supernatant was diafiltrated against PBS buffer with a filter cutoff of 10 kDa, 
supplemented with a “complete” protease inhibitor cocktail (Roche).  
IV.3.1.3 Purification of sE2 
Initial purification of both supernatants from transient transfection and stable cell line are 
achieved by Ni-NTA affinity purification (Qiagen). After immobilization of the protein, the 
column was washed with wash buffer (100mM K2HPO4/KH2PO4, pH 8.0, 300mM NaCl) 
Chapter IV: Materials and Methods 
94 
and eluted with stepwise elution buffer (wash buffer supplemented with 25, 50, 75, 250mM 
imidazole). The protein was then buffer changed into 50mM Tris-HCl, pH 8.0, with a Viva 
spin 20 filter (cut off at 10kDa). Cation exchange chromatography (MonoS HR10/10, GE, 0-
1M NaCl, 30 column volumes) was performed, followed by a size exclusion chromatography 
(Superdex 200 HR 10/300, GE) with a buffer containing 50mM citric acid, pH5.4, 200mM 
NaCl. The purification results were analyzed with SDS-PAGE and Western Blot. For 
Western Blot test, anti-His6-tag mouse monoclonal antibody (Novagen, dilution 1:1000) was 
used as the first antibody and AP-conjugated Anti-Mouse IgG (H+L) (Promega, dilution 
1:7500) was used as the second antibody, BCIP and NBT were added into staining solution. 
For analyzing sE2 characters, non-reduced SDS-PAGE (loading buffer without BME and no 
boiling) and Blue Native PAGE (NativePAGE™ Novex® Bis-Tris gels, 4-16%, Invitrogen) 
were also performed. 
IV.3.1.4 Deglycosylation and crystallization 
HCV sE2 was deglycosylated by EndoHf (NEB) the deglycosylation reaction system was 
prepared according to the user manual with a protein: EndoHf ratio 70 to 1. The reaction 
mixture was incubated at 37 °C for 2 h or at 4°C over night. The deglycosylated product was 
then analyzed by SDS-PAGE and followed by another size exclusion chromatography with 
(Superdex 75 10/30, GE) a buffer containing 50mM citric acid, pH 5.4, 200 mM NaCl. 
Purified protein has been concentrated with a Viva Spin 2 filter (10kDa cut off) to 5mg/ml, 
commercial screens were set up with Honeybee dispenser. 
IV.3.2 Cloning, expression and purification of human SRB1 ETD 
IV.3.2.1 Transient expression of Fc fusion SRB1 
Human SRB1 ETD (33-420) was cloned into pYD11 vector, which containing a PreScission 
protease cleavage site and a C-terminal hFc (Fc fragment of human IgG) coding sequence. 
Transient transfection protocol with HEK 293 cells was the same as II.C.1.1. 
IV.3.2.2 Insect cell expression system for SRB1 
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Human SRB1 ETD (residues 33 - 433) was cloned into pFlpBtM II donor vector, 
recombinant bacmids were generated using the Tn7 transposition method in bacmids of 
EMBacY (MBY) system, which includes a YFP-gene as a maker for infection monitoring 
(Meyer et al., 2013; Trowitzsch et al., 2010). Sf21 (DSMZ #ACC 119) suspension cultures 
were cultivated in ExCell420 (SAFC) on orbital shakers at 100 rpm at 27°C using a 2.5 cm 
orbit. 1 hour before transfection, 0.5 ×10
6
 cells/well were seeded into 6-well-plates. For each 
transfection, 10µl Superfect (Qiagen) and 2µg isolated bacmids were mixed in 100 µl 
ExCell420 medium. After incubation at RT for 20 min, the mixture was added on to adherent 
cells. 5 hours after infection, the transfection medium was replaced with fresh medium. The 
cell supernatant was harvested 3-5 days post transfection by monitoring YFP expression, the 
virus titer was determined by plaque assay.  For larger scale protein expression, Sf21 
suspension cultures were prepared with an initial cell density of 0.5×10
6
 cells/mL. The cells 
were infected with a MOI between1-3 or 10% of P1 virus stock. The cells were harvested 3-4 
days post transfection by low speed centrifugation. Cell pallets were suspended in lysis buffer 
(50 mM Na-Phosphate, 300 mM NaCl, 5 mM imidazol, 0,5% NP40, 3 mM β-
mercaptoethanol supplemented with 10 µg DNaseI, and a “Complete” protease inhibitor 
cocktail (Roche)), the supernatant was centrifuged at an ultra-speed 30 000 g for 1 hour. 
IV.3.2.3 Purification of SRB1 ETD 
Protein A Affinity Chromatography was used for isolation of Fc fusion constructs, strep-
tactin affinity Chromatography (Jena Bioscience) was performed with insect cells’ 
supernatant. Anion exchange chromatography (MonoQ HR10/10, GE, 0-1M NaCl, 30 
column volumes) was performed and followed by a size exclusion chromatography (50mM 
Tris/HCl, pH 7.6, 200mM NaCl). Analysis of protein expression and purification were 
performed by SDS-PAGE and Western Blot. For Western Blot experiment, HRP- conjugated 
goat anti-human IgG (Fc specific) antibodies were diluted 1 to 10 000 times and incubated at 
37℃ for 1h. Lumi-light Western Blotting substrate (3ml substrate A and 3ml substrate B) 
was added on to Polyvinylidene fluoride (PVDF) membrane, after incubation at RT for 5min, 
the membrane was screened with LAS-3000 imager system (Fujifilm). 
IV.3.2.4 Functional analysis 
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HCV infection competition tests were done in Twincore, Hannover, by Dr. Dorothea 
Bankwitz. Hun 7.5 cells were seeded in 96-well plate 24 h prior to infection. Pre-incubation 
with Jc1, which contains Renilla-Luc as a reporter was added into Huh 7.5 cell culture. 
Inoculation of 100 µl virus and test proteins, and incubate for 4 h. 72 h later, luciferase 
activity was assayed according to (Koutsoudakis et al., 2006). 
IV.3.2.5 Limited proteolysis 
Limited proteolysis was performed using purified protein from transient transfection. A series 
(1:10, 1:100, 1:1000) of each protease (trypsin, chymotrypsin and pepsin) were diluted in 
dilution buffer (10mM HEPES and 500mM NaCl). 100 μg purified Fc-SRB1 protein was 
mixed with 10μl of each diluted protease (correspond to 1μg, 0.1μg, 0.01μg for each 
protease), incubate at RT for 30 min. Analyze the digest effect on SDS-PAGE, load protease 
as control. The protein bands from SDS-PAGE were blotted onto a PVDF membrane, stained 
with Ponceau S and send for N- terminal sequencing. 
IV.3.3 Prolegumain and legumain 
IV.3.3.1 Expression and purification of prolegumain  
During our experiment of constructing stable cell lines with CHO lec 3.8.2.1, we found it 
constitutively secreting large amount of prolegumain into the culture media. The secreted 
prolegumain has the binding ability to Ni-NTA, protein A and strep-tactin resins. 
Conditioned medium (20 L) was produced with CHO lec 3.8.2.1cell line by continuous 
perfusion with a 2.5 L bioreactor. Cell supernatant was diafiltrated against Buffer A (50mM 
NaHPO4, pH 7.6, 300mM NaCl) with a filter cutoff of 10 kDa. The concentrated cell 
supernatant was then loaded on a 5 ml Ni-NTA column, washed with 100ml buffer B (50mM 
NaHPO4, pH 7.6, 300mM NaCl, 30mM Imidazole), and eluted with 50ml Buffer C (50mM 
NaHPO4, pH 7.6, 300mM NaCl, 300mM Imidazole). Anion exchange chromatography and 
size exclusion chromatography were employed for further purification. Prolegumain has been 
verified by Mass Spectroscopy and N-terminal protein sequencing.  
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IV.3.3.2 Deglycosylation of prolegumain and its self-cleavage into legumain 
Deglycosylation of prolegumain (1mg) with EndoHf (20mU) was carried out in sodium 
acetate buffer at pH 5.4, overnight at 37°C. After deglycosylation, another size exclusion 
chromatography was used to remove EndoHf and glycan residues. During deglycosylation at 
pH 5.4, an auto-cleavage into legumain also carried on at the same time.  
IV.3.3.3 Crystallization 
5mg/ml of purified legumain were used for crystallization tests. Crystallization screens were 
set up with commercial screens with Honeybee dispenser. Rod-shape crystals were observed 
at different conditions from initial screens. Three crystallization conditions have been chosen 
for fine screens. Condition1 contains 0.03M MgCl2, 0.03M CaCl2, 10% PEG 20 000, 20% 
PEG550 MME and 0.1 M MOPS/HEPES buffer, pH 7.5. Condition 2 has similar ingredients 
with condition 1 but has a buffer pH of 8.5. Condition 3 contains 0.1 M NaCl, 23% PEG 
3350 and 0.1 M MOPS buffer, pH 6.5. The crystal was fished and cryo-protected and quickly 
dipped into liquid nitrogen for X-ray diffraction data collection. 
IV.3.3.4 Data Collection, Processing, and Structure determination 
The X-ray diffraction data were collected at beamline P11 of PETRAPETRA III Hamburg, 
Germany) at wavelengths of 1.033191 Å. Data were processed with XDS package (Kabsch, 
2010) Molecular replacement was carried out with Phaser_MR against human prolegumain 
(PDB code: 4FGU) and legumain (PDB code: 4AWA). Prior to molecular replacement, non-
conserved amino acids side chains of search models were pruned with Chainsaw. The initial 
model was improved by iterative steps of manual building in Coot and refinement in 
Phenix.refine. Refinement was stopped after converging values of Rwork and Rfree were 
reached.  
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Appendix 
 
Figure S1: Structure based sequence alignment of YePykF and YePykA. Domains are separated by dashed 
lines. A domain: cyan; B domain: green; C domain: pink.  
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Figure S2: Electron density maps of YePykF ligand F16BP. (a) 2Fo-Fc map contoured at 1σ, blue 
mesh. (b) Fo-Fc map contoured at 3σ, green mesh. (c) The fit of F16BP into electron density maps. 
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